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ABBREVIATIONS
α2M α2-macroglobulin
ALL acute lymphoid leukemia
AML acute myeloid leukemia
APL acute promyelocytic leukemia
ATF aminoterminal fragment (of uPA)
ATRA all-trans retinoic acid
BSA bovine serum albumin
CD cluster of differentiation
CLL chronic lymphocytic leukemia
CML chronic myeloid leukemia
CNS central nervous system
CRP C-reactive protein
D1 domain 1 of uPAR
D2D3 domains 2+3 of uPAR
DBSA Dulbecco's balanced salt solution containing BSA
DEX dexamethasone
DIC disseminated intravascular coagulation
ECM extracellular matrix
ELISA enzyme-linked immunosorbent assay
FAB French-American-British (classification)
FACS fluorescence-activated cell sorter
FBS fetal bovine serum
FITC fluorescein isothiocyanate
GAPDH glyceraldehyde-3-phosphate-dehydrogenase
GPI glycosyl-phosphatidylinositol
HMEC-1 human microvascular endothelial cells
HUVEC human umbilical vein endothelial cells
ICAM intercellular adhesion molecule
Ig immunoglobulin
IL interleukin
IFN interferon
ITP idiopathic thrombocytopenia
MDS myelodysplastic syndrome
MMP matrix metalloproteinase
PA plasminogen activator
PAGE polyacrylamide gel electrophoresis
PAI plasminogen activator inhibitor
plg plasminogen
PBS phosphate-buffered saline
PMA phorbol 12-myristate 13-acetate
PBMC peripheral blood mononuclear cell
RA retinoic acid
RAR retinoic acid receptor
SDS sodium dodecyl sulphate
SD standard deviation
SE standard error
SSC standard saline citrate
suPAR soluble uPAR
TGF transforming growth factor
TNF tumor necrosis factor
tPA tissue-type plasminogen activator
uPA urokinase-type plasminogen activator
uPAR uPA receptor
WBC white blood cell
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SUMMARY
Adhesion and invasion are important processes both for normal and malignant cells.
However, malignant cells usually differ from normal cells in their capability to produce large
amounts of proteolytic enzymes, which they use in cell invasion to degrade extracellular matrix
proteins. The plasminogen activation cascade is known to be one of the most important
extracellular proteolytic mechanisms in adherent tumors, whereas its role in leukemia have
remained unclear. It has been thought that the traditional pericellular proteolytic roles of
plasminogen activators are unimportant in leukemia, since these cells are growing in
"suspension" in the circulation, and they are not invading in the same manner as do adherent
tumor cells. It is very likely, however, that the plasminogen activation cascade may play an
important role in leukemia as well, because in some circumstances leukemia cells are also
invading extramedullary organs and even the central nervous system. In addition, novel non-
proteolytic roles for the plasminogen activation system have recently been discovered. We
therefore chose to evaluate the roles of the plasminogen activation (PA) system and especially
the role of the urokinase receptor (uPAR) in leukemia and to analyze the invasion mechanisms
of leukemia cells.
The first goal of the project was to characterize the significance of plasminogen activation in
acute promyelocytic leukemia (APL) in cell culture (I). We found that plasmin is formed on the
surface of APL cells, and retinoic acid (RA), which is used in the treatment of APL, stimulated
transiently plasmin generation. Interferons potentiated RA in its effects on plasminogen
activation, and dexamethasone, which relieves the side-effects of RA therapy, totally suppressed
the effect of RA on plasminogen activation. These results suggest that plasmin with a potent
protease activity can interfere with the normal fibrinolytic balance and be part of a cascade
leading to the excessive bleeding problems encountered with APL patients. Increase in uPAR
mRNA expression caused by RA fits in well with the results of those clinical studies in which
infiltration of maturing myeloid cells into various organs has occurred in some APL patients
with retinoic acid syndrome.
The extravasation of APL cells was characterized in a newly established three-dimensional
organotypic model for vessel wall in vitro (II). We found that RA induced rapid extravasation
of APL cells, and that ICAM-1 antibodies could totally inhibit this extravasation process. In
addition to APL extravasation, we also examined the extravasation of normal mononuclear cells
and blast cells ex vivo from leukemia patients and evaluated the roles of certain adhesion
molecules (ICAM-1, -2, -3, CD11a, and CD18) in these processes (II). Our results show that
extravasation of both normal mononuclear cells and leukemia cells could be inhibited with
ICAM-1 antibodies, whereas antibodies against the other adhesion molecules had no significant
effects. Purified soluble ICAM-1 (sICAM-1) had no effect on this extravasation. Furthermore,
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we determined the presence of soluble adhesion molecules (sICAM-1 and sICAM-2) in plasma
samples of acute leukemia patients at diagnosis and found that although the levels were
increased, they showed no correlation with the numbers of tumor cells in circulation or with the
chemosensitivity of blast cells.
Because our in vitro results in APL showed that the PA system and especially the levels of
uPA/uPAR varied during RA treatment (I), we decided to analyze the presence of these
components in vivo in leukemia
 
patient samples (III, IV). We examined blood samples
 
from
patients with newly diagnosed acute leukemia in order to define whether the components of the
PA system can be used as tools in leukemia diagnosis and prognosis. Our main findings were
that uPAR correlated with the type of leukemia, since only patients with acute myeloid leukemia
(AML) and with hybrid leukemia expressed uPAR on their blast cell surface. Blast cells from
acute lymphoid leukemia (ALL) patients were negative for uPAR (III).
 
Further, soluble uPAR
(suPAR) was significantly elevated
 
in the plasma of patients with acute leukemia, and in AML
patients, high levels of suPAR
 
correlated with poor prognosis (III).
Thus far, no longitudinal studies have addressed the behavior of uPAR during treatment, and
the source of the excess suPAR in cancer patients remains undetermined. We therefore
continued our project in acute leukemia and measured uPAR in the plasma, urine, and tumor
cells of patients with acute leukemia during chemotherapy (IV). Our results showed for the first
time that the amount of plasma suPAR correlated both with tumor-cell count and with the
content of uPAR in cell lysates. We also found that plasma suPAR levels decreased rapidly
when tumor cells were removed from the circulation with chemotherapy, suggesting that
circulating tumor cells are the source of the suPAR in plasma and in urine samples.
Furthermore, we observed that increased amounts of uPAR fragments could be found in the
body fluids of acute leukemia patients. Since proteolytic cleavage of uPAR induces a potent
chemotactic response in vitro, it is possible that these fragments may play a role in the
pathophysiology of acute leukemia.
We studied next the release of suPAR from various cell types in culture conditions, to
understand the cellular origin of the plasma suPAR in healthy individuals (V). Our results
showed that suPAR can be found in the culture medium of blood mononuclear cells and
endothelial cells. Furthermore, we noticed that enhanced amounts of suPAR were released from
the cell surface when either blood mononuclear cells or thrombocytes were cultured in contact
with endothelial cells, whereas co-culture without cell-cell contact failed to enhance suPAR
release. We also observed that suPAR fragments were present in co-culture growth media.
These results suggest that normal plasma suPAR is produced by endothelial and blood
mononuclear cells and that its release is enhanced when cells are in physical contact with each
other, implying that receptor shedding is a possible regulatory mechanism in cell adhesion.
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INTRODUCTION
The plasminogen activation (PA) system comprises several activators, inhibitors, and
receptors, all of which have strictly controlled roles (see Fig. 1). Under physiological conditions,
activation of plasminogen to proteolytically active enzyme plasmin takes part in many processes,
such as in fibrinolysis, cell migration, wound healing, trophoblast invasion, angiogenesis, tissue
destruction, and activation of growth factors and of other proteolytic enzymes. Many of these
roles of the PA system in normal physiology are equally important in cancer. Cancer cells need
to adhere to basement membranes and subsequently detach from them to be able to move on in
the extracellular matrix (ECM). They need to degrade various proteins and maintain their own
growth by activating various growth factors and enzymes.
In leukemia, the production of normal hematopoietic cells is disrupted, and in the bone
marrow, undifferentiated leukemic cells overgrow normal differentiating blood cells. Gradually,
these malignant cells burst from the bone marrow into the circulation and in some cases into
other organs as well (e.g., skin, gums, and the central nervous system). Although the importance
of the PA system, and particularly the essential role of urokinase-type plasminogen activator
(uPA), is well established in solid tumors, the significance of pericellular proteolysis is less clear
in hematopoietic malignancies. Therefore, in this work, we have chosen to study the importance
of the PA system and of various adhesion molecules in leukemia.
Fig. 1. Overview of uPA-mediated plasminogen activation system. Plasminogen is a
proenzyme that needs to be activated to be able to degrade extracellular matrix proteins. In human beings,
there exist two main plasminogen activators: urokinase-type plasminogen activator (uPA) and tissue-type
plasminogen activator (tPA). In addition to the activators are also two inhibitors, PAI-1 and –2.
uPAR is a specific cell-surface receptor for uPA. Binding of uPA to uPAR localizes plasminogen
activation at the cell surface. In addition to its function in proteolytic cascades, uPAR is also associated
with several important adhesion proteins such as vitronectin and integrins and plays an important role in
cell migration and adhesion.
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REVIEW OF THE LITERATURE
NORMAL HEMATOPOIESIS AND ITS CONTROL
The life-span of normal blood cells is limited, and these cells are constantly produced in the
bone marrow. It has been estimated that approximately 0.5-1x1012 new blood cells are formed
every day in a healthy adult (Gale and Butturini, 1992). Furthermore, in response to various
stimuli (hypoxia, infection, bleeding) the production of certain blood cell types is multiplied. The
real hematopoietic stem cell has not been characterized, but recent reports suggest that blood
cells and endothelial cells may have a common progenitor cell, called the hemangioblast (Choi et
al., 1998). In clinical use, CD34-positive cells are regarded as hematopoietic stem cells, although
it is likely that only a small fraction of these cells are true hematopoietic stem cells. However,
these cells are able to differentiate into mature blood cells and to repopulate the bone marrow.
They are used as stem-cell support in connection with high-dose chemotherapy for various
cancers. Pluripotent stem cells give rise to myeloid and lymphoid precursor cells, which in turn
can differentiate into mature granulocytes, erythrocytes, monocytes, platelets, and T- and B-cells
(see Fig. 2). Several humoral factors have been characterized which are able to regulate the
growth and differentiation of hematopoietic precursor cells. Various interleukins, erythropoietin,
trombopoietin, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage
colony-stimulating factor (M-CSF), and granulocyte colony-stimulating factor (G-CSF) can
induce the proliferation of hematopoietic cells (Groopman et al., 1989; Metcalf 1991; Ogawa
1993). In contrast, interferons, transforming growth factor-β (TGF-β), and macrophage
inflammatory protein-1 reduce the production of hematopoietic cells (Fortunel et al. 2000). In
addition, retinoic acid and interferons can induce differentiation of various leukemia cell types
(Warrel et al., 1991).
Neutrophil
Fig. 2. Hematopoiesis
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LEUKEMIA
Classification
In leukemia, the control of the growth of leukemic cells is disrupted, and gradually, these cells
overgrow normal differentiating blood cells. These immature cells subsequently burst into the
circulation and also into other organs. Leukemias can be roughly divided into acute and chronic
leukemias based on their degree of cell-maturation, and myeloid and lymphoid leukemias based
on the lineage of differentiation of these malignant cells. In chronic leukemias, malignant cells
usually resemble mature blood cells and/or their precursors, but in acute leukemias the
differentiation of blood cells ceases at much earlier, primitive stages.  In acute leukemias, the
French-American-British (FAB) classification is widely used (Bennett et al., 1976), although a
new classification system of hematological malignancies has also been described (Harris et al.,
1999). According to the FAB classification, acute myeloid leukemias (AML) are divided into
eight different subclasses (M0-M7), whereas in acute lymphoid leukemias (ALL) there are three
subclasses (L1-L3). However, in ALL, the FAB classification has very limited clinical value;
instead, the immunophenotypic classification is usually used. In adults, AML is the most
common (80%) acute leukemia. In contrast, in children, most acute leukemias are of lymphoid
origin. Yet, acute leukemia is, overall, quite a rare cancer compared to some solid tumors. In
Finland, the annual incidence of adult acute leukemia is about 150 new cases (3/105 inhabitants),
compared to about 3000 breast cancers (60/105 inhabitants) (Dickman et al., 1999).
The etiology of acute leukemia is largely unknown. No evidence exists of its inheritability,
although in some families it seems that the risk of developing leukemia is higher than in others
(Cartwright and Staines, 1992). Some chemicals (such as benzene and ethylene oxide),
irradiation, and cytotoxic agents are known risk factors (Cartwright and Staines, 1992), because
these can cause gene alterations and chromosomal instability that can block normal blood cell
differentiation. In various types of leukemias, several characteristic chromosomal abnormalities
occur, and some of these abnormalities can be used as markers for diagnosis, such as the 15;17
translocation in acute promyelocytic leukemia (Larson et al., 1984; Grignani et al., 1994).
Furthermore, some chromosomal abnormalities are prognostic markers, such as the Philadelphia
chromosome (t9;22) in ALL.
Patients with acute leukemia are usually treated with combination chemotherapy, which
consists of several cycles of high-dose cytotoxic agents. After the intensive induction and
consolidation phase, patients with ALL usually receive low-dose maintenance therapy. In
addition to chemotherapy, a common treatment is stem-cell transplantation. Treatment results
have considerably improved during the last two decades, and at present, approximately 30 to
40% of adult patients under the age of 65 years become long-term survivors. In childhood acute
leukemia the situation is even more optimistic: of every four children with acute leukemia, three
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are cured. Without treatment, median survival time of acute leukemia patients is only 2 to 3
months.
Clinical findings
Most of the signs and symptoms of acute leukemia relate to cytopenias caused by deficient
production of normal blood cells. The shortage of thrombocytes can cause petechias and
bleeding diathesis, and the shortage of normal leukocytes can predispose patients to infections.
Fatigue and fever are relatively common. In addition, some of the symptoms are caused by
leukemia cells able to infiltrate various organs, such as the skin and gums. Furthermore,
infiltration of blast cells into the central nervous system is a feared and often fatal complication.
In addition to these symptoms, the intensive treatment of acute leukemia causes numerous other
symptoms. On the other hand, patients with chronic leukemia are often asymptomatic for a long
time, with their abnormal blood leukocytosis found only by accident during routine laboratory
tests. At more advanced stages, problems caused by the large mass of abnormal cells, infections,
and also immunological problems may appear. But overall, the general condition of chronic
leukemia patients is often better than that of patients with acute leukemia.
Acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia is a rare subtype of AML (FAB-type: M3), which accounts
for 10% of acute myeloid leukemias (Warrell et al., 1993). It is characterized by a reciprocal
15;17 chromosomal translocation (Larson et al., 1984; Grignani et al., 1994). The translocation
breakpoint on chromosome 17 resides within the gene encoding the retinoic acid receptor (RAR-
α). This fuses to the PML gene in chromosome 15 and results in production of a fusion protein
that blocks the normal myeloid differentiation (Grignani et al., 1993). APL patients more often
have coagulation and bleeding problems than do patients with other types of acute leukemia.
This hemorrhagic diathesis is thought to result either from disseminated intravascular
coagulation or from abnormal fibrinolysis (Tallman and Kwaan, 1992).
APL patients are treated with all-trans-retinoic acid (ATRA) in addition to normal
chemotherapy (Castaigne et al., 1990; Warrell et al., 1991; Fenaux, 1993; Tallman et al., 1997;
Warrell, 1997). ATRA induces differentiation of leukemic cells into mature granulocytes in vitro
and in vivo, and it also reduces APL patient’s bleeding tendency (Dombret et al., 1993). It is
often a better-tolerated treatment than normal chemotherapy, but about one-third of the patients
encounter severe side-effects from RA treatment, called the retinoid acid syndrome (RA
syndrome) (Frankel et al., 1992). The patients with RA syndrome experience fever, bleeding
problems, and leukocytosis. Dexamethasone treatment and discontinuation of ATRA
administration usually relieve these side-effects, but the mortality is higher among these patients
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than among patients without the syndrome (De Botton et al., 1998). APL patients, overall, show
better survival than do other AML patients (Grignani et al., 1994).
PLASMINOGEN ACTIVATION SYSTEM IN GENERAL
PLASMINOGEN AND PLASMIN
Plasminogen is a proenzyme that can be converted to active plasmin, capable of cleaving
many extracellular proteins (Pöllänen et al., 1991; Collen, 1999). The gene for human
plasminogen is located in the long arm of chromosome 6 (Lijnen and Collen, 1995). The 92 kDa
native form of plasminogen, produced mainly by liver cells, is abundantly present in most
extracellular fluids and in plasma at a 2.0 µM concentration (Lijnen and Collen, 1995). In its A-
chain, plasminogen has 5 homologous kringle domains (Ponting et al., 1992), which have high
affinity for lysine, and they mediate the binding of plasminogen to fibrin and to the cell surface.
Plasminogen-type kringles are also present in other proteins, such as in hepatocyte growth factor
(HGF) and in prothrombin, as well as in tPA and uPA (Ponting et al., 1992). In addition to
kringle domains, plasminogen has a highly active serine protease domain in its B-chain in the C-
terminal end (Ponting et al., 1992). The cleavage of the peptide bond between Arg-560 and Val-
561 converts the one-chain proenzyme plasminogen to the two-chain structure of plasmin. The
plasminogen activators, tPA and uPA, mediate this specific cleavage process (Danø et al., 1985;
Pöllänen et al., 1991) (see Fig.1 and Table 1).
Plasmin is a trypsin-like serine protease with wide substrate specificity. In addition to fibrin
degradation, plasmin can cleave several ECM proteins, such as fibronectin, thrombospondin, and
laminin. Plasmin can also indirectly participate in ECM degradation by activating other proteases
(latent procollagenases and other metalloproteinases) (Werb et al., 1977; Pöllänen et al., 1991).
Knockout studies have revealed that plasminogen is not essential in the embryonic development
of mice, since plg-/- mice are born with a normal appearance and survive to adulthood, although
they develop spontaneous fibrin lesions due to impaired thrombolysis (Ploplis et al., 1995;
Rømer et al., 1996). In addition to fibrin formation, plg-/- mice show high mortality,
spontaneous gastrointestinal lesions, and impaired wound healing. Interestingly, studies with plg
and fibrinogen double-knockout mice showed that pathology associated with plasminogen
deficiency was eliminated with the simultaneous fibrinogen deficiency (Bugge et al., 1996),
suggesting that the most important role of plasminogen is fibrinolysis.
The reason for the unexpected normal embryonic development of plg-/- mice may be that
there is a functional overlap between plasmin and other extracellular proteinases, which may
compensate for the loss of plasmin-mediated proteolysis. This view is strengthened by recent
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studies that show that simultaneous inhibition of matrix metalloproteases in plg-/- mice
completely arrests wound healing (Lund et al., 1999). In contrast, those normal plg-/- mice
without any inhibition of MMPs show delayed wound healing, but eventually wound closure is
achieved.
PLASMINOGEN ACTIVATORS
Urokinase-type plasminogen activator (uPA)
In addition to tissue-type plasminogen activator, uPA is the main activator of plasminogen in
humans. In bacteria, there are also other plasminogen activators such as streptokinase and
staphylokinase (Rijken, 1995). The name urokinase points to urine, from whence uPA was first
purified. In addition to urine, uPA is also present in plasma (Wun et al., 1982b), but in a
relatively low concentration of 40 pM with a half-life of 5 min (Collen and Lijnen, 1991). The
gene for human uPA is located in the long arm of chromosome 10 (Rajput et al., 1985; Tripputi
et al., 1985) (see Table 1).
The 54 kDa protein is produced as a single-chain proenzyme (pro-uPA) (Wun et al., 1982a)
and is converted to the two-chain active form by plasmin, which in turn results in activation of
plasminogen to plasmin (Pöllänen et al., 1991). This conversion of inactive proenzyme to the
fully active enzyme is an important regulatory step in the uPA-mediated plasminogen activation
cascade. A large variety of cells can produce uPA in our body: blood leukocytes and also
endothelial cells, smooth muscle cells, epithelial cells, fibroblasts (Pöllänen et al., 1991; Camoin
et al., 1998; Collen, 1999). In contrast to these adherent cells, all of which produce proenzyme
the form of uPA, leukemia cells have an exceptional ability to produce active uPA (see page 33)
(Stephens et al., 1988; Tapiovaara et al., 1991; Stephens et al., 1992; Tapiovaara et al., 1996).
uPA comprises several domains (Danø et al., 1985). The growth factor domain is responsible
for the binding of uPA to its cellular receptor uPAR and has a homology to epidermal growth
factor. The kringle domain, with a homology to plasminogen, promotes binding to other
proteins, such as laminin (Stephens et al., 1992). The active site of uPA is located in the C-
terminal end in the catalytic domain, which has a homology to other serine proteinases. In
addition to plasmin, some other serine proteinases (such as trypsin and kallikrein) and cathepsin
B can also activate pro-uPA (Kobayashi et al., 1991; List et al., 2000).
uPA has a specific receptor on cell surfaces, uPAR (CD87) (Behrendt and Stephens, 1998).
It binds with high affinity both single- and two-chain forms of uPA as well as uPA in complexes
with inhibitors. Binding of uPA to its receptor enhances and localizes plasminogen activation on
the cell surface. While tPA is thought to be the main plasminogen activator in fibrinolysis, uPA
is thought to be the main activator of plasminogen in cell migration and cell invasion (Pöllänen et
al., 1991). Many studies in various cancers have shown that uPA is expressed in increased
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amounts by the tumor cells and especially at the leading front of migrating cells (Danø et al.,
1994) (See Fig. 1).
Since homozygous deficiencies of uPA or tPA have not been observed in humans, it had
been expected that inactivation of these genes in mice would lead to death during embryonic life.
However, just like plg-knockout mice, uPA knockouts appear normal at birth, suggesting that
uPA is not required for normal embryonic development (Carmeliet et al., 1994). Some of these
mice suffer from rectal prolapse and develop spontaneous ulceration and fibrin deposits more
often than do wild-type mice, but still had a normal life-span. Studies with tumors showed that
melanocytic neoplasms do not progress to malignant melanomas in uPA-deficient mice,
suggesting that uPA may be important in tumor progression (Shapiro et al., 1996). However, the
effects of uPA deficiency in these knockout mice were overall surprisingly small in the areas to
which uPA activity has traditionally been related. But knockout studies revealed some new
functions for uPA: uPA-/- mice failed to recruit inflammatory cells in response to inoculation
with pathogenic bacteria and developed uncontrollable lethal infection (Gyetko et al., 1996; Beck
et al., 1999). This suggests that uPA might play a role in inflammation and chemotaxis, as well.
Later, it has also been shown that in uPA knockout mice, T-cell activation and proliferation in
response to T-cell receptor-mediated signaling is impaired (Gyetko et al., 1999). This may
explain their impaired inflammatory response.
Tissue-type plasminogen activator (tPA)
tPA is thought to be the main activator of plasminogen in fibrinolysis (Danø et al., 1985). It
has 40% homology with uPA, and it is coded by a different gene located in the long arm of
chromosome 8, yielding a protein of 68 kDa (Rajput et al., 1985) (see Table 1). The growth
factor domain, kringle domain, and catalytic domain of tPA are similar to those of uPA, but in
addition, tPA also has a second kringle domain and an amino-terminal finger domain. This
difference in domain structure also has functional consequences, since the second kringle
domain, and partially the finger domain of tPA, are essential for its affinity to fibrin. When
bound to fibrin, the tPA catalytic activity is markedly enhanced, and it activates plasminogen
efficiently, resulting in dissolution of fibrin clots. This specific ability of tPA to locally activate
plasminogen on the surface of fibrin has led to its successful use as one thrombolytic therapy in
myocardial infarction and in ischemic stroke (National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Group, 1995).
In the circulation, tPA is found at a concentration of 70 pM with a half-life of 4 min (Lijnen
and Collen, 1995). It is also produced as a single-chain proenzyme, but differing from uPA, both
the single-chain and two-chain forms are active. Endothelial cells, keratinocytes, and some
leukocytes express and release tPA, but no specific high-affinity cell-surface receptor for tPA
has been characterized (Redlitz and Plow, 1995). Although uPA is related more closely to the
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pericellular proteolysis in malignancy, tPA has been shown to be the main plasminogen activator
produced by melanoma and neuroblastoma cells (Neuman et al., 1989; Bizik et al., 1993).
In addition to the function of tPA in fibrinolysis, new, possibly non-proteolytic roles for tPA
have been found in neural cell development and remodeling (Carroll et al., 1994). Neurons and
microglial cells have been shown to synthesize tPA in most areas of the developing murine brain,
and tPA is induced during cerebellar motor learning (Seeds et al., 1996). Furthermore, enhanced
tPA activity has been related to multiple sclerosis (MS) (Akenami et al., 1996; Akenami et al.,
1997), and it has been suggested that in MS, tPA can participate in neuronal demyelination
(Akenami et al., 2000). The first knockout studies revealed rather little of the function of tPA,
since these mice were normal at birth, had no macroscopic or histological abnormalities up to the
age of 14 months, and had a normal life span (Carmeliet et al., 1994). Only the lysis of
pulmonary plasma clots was significantly reduced. It is, however, possible that studies of
neuronal function in tPA knockouts reveal additional and more drastic changes, since it has
already been shown that tPA-/- mice are resistant to kainate-induced neurotoxicity (Tsirka et al.,
1995) and that neuronal migration in tPA knockouts is retarded (Seeds et al., 1999).
Table 1. Components of the plasminogen activation system
Component Chromosomal
location
Mol. weight
kDa
Amino acids Plasma conc.
Plasminogen 6q26-27 92 791 200 mg/L
uPA 10q24 54 411 0.002 mg/L
tPA      8q12 68 530 0.005 mg/L
uPAR 19q13 55 283 0.001 mg/L
PAI-1 7q21-22 52 379 0.050 mg/L
PAI-2 18q21 46/60-70 393 <0.005 mg/L
See related reviews (Lijnen and Collen, 1995; Rijken, 1995; Collen, 1999).
INHIBITORS OF PLASMINOGEN ACTIVATORS AND OF PLASMIN
Plasminogen activator inhibitors 1 and 2 (PAI-1 and -2) are the main inhibitors of uPA and
tPA (Andreasen et al., 1990), although protease nexin 1 and PAI-3 are also known to affect
plasminogen activators to some extent. PAI-1 and -2 are also quite specific for uPA and tPA and
react only very slowly with other serine proteases.
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Plasminogen activator inhibitor 1 (PAI-1)
The production of PAI-1 was originally described in endothelial cells, and therefore was
initially designated as endothelial cell type PA-inhibitor (Hekman and Loskutoff, 1985;
Sprengers and Kluft, 1987). However, many other cell types produce PAI-1 as well (e.g.,
fibroblasts, smooth-muscle cells, and many tumor cells) (Sprengers and Kluft, 1987; Andreasen
et al., 1990). PAI-1 is a single-chain 52 kDa glycoprotein and is present in plasma at a 200 pM
concentration, although the concentrations vary greatly in different individuals and depending on
time of day. Part of the plasma PAI-1 is thought to be released by platelets. The gene for PAI-1
is located in the long arm of chromosome 7 (Rijken, 1995) (see Fig.1 and Table 1).
PAI-1 reacts both with single- and two-chain forms of tPA (Andreasen et al., 1990). This
leads to the formation of irreversible enzyme complexes with no proteolytic activity. It has been
thought that PAI-1 reacts only with the two-chain form of uPA, but some evidence also exists
that PAI-1 may form reversible complexes with the single-chain type of uPA as well
(Manchanda and Schwartz, 1995). It can also bind receptor-bound uPA, but fibrin-bound tPA
has been shown to react much more slowly with PAI-1 than does free tPA (Rijken, 1995). The
main function of PAI-1 in circulation has been thought to be the regulation of tPA activity, and
by this function, it proves an important regulator of fibrinolysis. The results obtained from
various thrombotic disorders strengthen this view: patients with coronary heart disease and
myocardial infarction show elevated plasma PAI-1 levels (Juhan-Vague and Alessi, 1993).
PAI-1-/- knockout mice are viable as are the other PA-system knockout mice (Carmeliet et
al., 1993). They resemble tPA-knockout mice in the sense that no macroscopic or histological
abnormalities are observable in their organs. However, there are some studies showing that PAI-
1 deficiency in humans leads to excessive bleeding disorders (Diéval et al., 1991). Recent results
on tumorigenesis in PAI-1 knockout mice have shown that PAI-1 deficiency prevents cancer cell
invasion and tumor angiogenesis (Bajou et al., 1998). This fits in well with the clinical
observation showing that high PAI-1 level is a poor prognostic marker of various cancers.
In the blood, most of the circulating PAI-1 is bound to vitronectin. In addition, vitronectin in
the ECM has been shown to co-localize with PAI-1. The somatomedin B domain in vitronectin
is responsible for PAI-1 binding (Deng et al., 1996); uPAR binds to this same domain of
vitronectin and competes with PAI-1 binding. It has been suggested that PAI-1 plays a central
regulatory role in uPAR/vitronectin-mediated cell adhesion, since an excess of PAI-1 will
compete with and replace uPAR from its association with vitronectin, and in turn, an excess of
uPA will neutralize PAI-1 and again promote cell adhesion (Loskutoff et al., 1999).
PAI-1 binding to vitronectin prevents integrin binding to vitronectin as well. Active PAI-1 can
block vitronectin binding to vitronectin receptor αvβ3 and in this manner, inhibit cell migration
(Stefansson and Lawrence, 1996). However, when uPA binds to PAI-1, it abolishes the ability of
PAI-1 to bind to vitronectin and restores cell migration by allowing vitronectin again to bind
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integrins (Loskutoff et al., 1999). This suggests that the function of uPA at the leading edge of
migratory tumor cells is not only to enhance plasminogen activation and pericellular proteolysis,
but also to reinforce cell migration by blocking PAI-1 binding to vitronectin. However, because
the synthesis of PAI-1 is rapidly stimulated by a variety of growth factors and cytokines, it is
likely that PAI-1 binding and release from vitronectin, or from the extracellular matrix in general,
occurs in a stepwise manner, and therefore, the pro- and contra-adhesive signals are following
each other in a continuous cascade. Taken together, through this vitronectin-binding ability, PAI-
1 is an important regulator of cell adhesion and migration.
Plasminogen activator inhibitor 2 (PAI-2)
PAI-2, earlier called placental-type plasminogen activator inhibitor, as it was originally
purified from human placenta, is a 46 kDa protein expressed by monocytes, keratinocytes, and
placental syncytiotrophoblasts (Sprengers and Kluft, 1987; Andreasen et al., 1990). It also has
another higher molecular weight protein form (60-70 kDa), which is found extracellularly and
has a higher degree of glycosylation. The normal PAI-2 plasma levels are very low (<70 pM) or
even undetectable, but during pregnancy the levels increase (Rijken, 1995). The PAI-2 gene has
been mapped to chromosome 18 (Rijken, 1995) (see Table 1).
PAI-2 mainly inhibits uPA (Baker et al., 1990), as it has been shown to react considerably
more slowly with tPA than with uPA. In vivo functions of PAI-2 are less well known than those
of PAI-1. Bacterial endotoxins induce PAI-2 expression in monocytes, suggesting that PAI-2
may be involved in inflammatory processes (Belin, 1993). Furthermore, PAI-2 locally inhibits
cancer cell degradation of basement membranes (Baker et al., 1990). However, PAI-2 knockout
mice have not been described in the literature, maybe because no major important roles for PAI-
2 have thus far, been found.
α2-antiplasmin
α2-antiplasmin is the main inhibitor of plasmin in the plasma. The plasma concentration of
α2-antiplasmin is high (1 µM) (Lijnen and Collen, 1995), and it is able to react rapidly with
plasmin. It has been calculated that the half-life of free plasmin in the blood is only 0.1 sec
(Collen, 1999). The gene for α2-antiplasmin has been located in the short arm of chromosome
18, and the protein produced has a molecular weight of 70 kDa (Lijnen and Collen, 1995).
In vivo, α2-antiplasmin deficiency has been related to serious bleeding complications (Collen,
1999). Homozygous deficiency has been shown to be associated with severe hemorrhagic
diathesis, whereas only mild bleeding problems are seen with the heterozygotic phenotype. In
addition, enhanced fibrinolysis in disseminated intravascular coagulation in APL patients is
possibly caused by acquired α2-antiplasmin deficiency (see page 34) (Dombret et al., 1993;
1995).
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α2-macroglobulin
In addition to α2-antiplasmin, α2-macroglobulin (α2M) is also an important inhibitor of
plasmin in plasma (Borth, 1992). However, it is rather unspecific for plasmin, as it is able to
inhibit almost any type of proteinases. α2M is a high molecular-weight (725 kDa) glycoprotein,
and its plasma concentration is 3 µM. The gene for α2M is located in the short arm of
chromosome 12 (Collen and Lijnen, 1991).
α2M is produced by a large variety of cells: fibroblasts, monocyte-macrophages, hepatocytes,
astrocytes (Borth, 1992). Some tumor cells, e.g., melanoma and sarcoma cell lines, have also
been observed to secrete this protein (Bizik et al., 1986). α2M is not only a broad-spectrum
protease inhibitor. It functions also as a carrier protein for several growth factors, such as
transforming growth factor β (TGF-β) and platelet-derived growth factor (PDGF) (Borth,
1992).
Cellular receptor for α2M (α2MR) is identical with a low-density lipoprotein receptor-related
protein (LRP). This receptor is a multi-functional protein also capable of binding and
internalizing uPA-uPAR-PAI-1 complexes. In addition, it has been defined as a monocyte
differentiation marker, because it appears at an early stage of monocyte differentiation and is not
expressed by other types of blood cells (Borth, 1992).
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (uPAR)
Structure and general function of uPAR
A high affinity and specificity cell-surface receptor for uPA, uPAR, was first discovered in
monocytes (Vassalli et al., 1985) and in monocytoid U937 cells (Stoppelli et al., 1985; Vassalli
et al., 1985), and since then it has been characterized in a variety of cell types such as
granulocytes, endothelial cells, keratinocytes, fibroblasts, and smooth-muscle cells (Blasi et al.,
1994; Danø et al., 1994; Behrendt and Stephens, 1998). uPAR binds to the cell surface via a
glycosyl-phosphatidylinositol (GPI) anchor (Ploug et al., 1991) (Fig. 3) and thus has no
intracellular portion. The heavily glycosylated protein consists of three homologous domains
(D1-D3), which have different binding properties for various ligands. The amino-terminal
domain D1 is responsible for the binding of uPA (Behrendt et al., 1990; Behrendt et al., 1991),
and the other two, D2 + carboxyterminal domain D3, are important in vitronectin binding (Wei
et al., 1994). However, the full-size receptor is required for high-affinity interactions with both of
these ligands (Ploug et al., 1994; Wei et al., 1994; Behrendt et al., 1996; Riittinen et al., 1996;
Høyer-Hansen et al., 1997a; Sidenius and Blasi, 2000). The uPAR gene, encoding a 55 kDa
protein, is located in the long arm of chromosome 19 (Collen and Lijnen, 1991) (see Figs. 1, 3
and Table 1).
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uPAR binds both single- and two-chain forms of uPA, as well as uPA complexed with PAI-
1. uPA/PAI-1 complexes will be internalized rapidly (Olson et al., 1992) when bound to the
receptor, but free uPA remains attached to the cell surface. This internalization facilitates
recycling of the receptor, since the receptor is internalized together with the activator-inhibitor
complex, and subsequently, free receptor is recycled to the cell surface (Nykjaer et al., 1997).
α2MR/LRP is involved in this endocytosis process.
At first, uPAR was thought to occur only in its full-size form on the cell surface, but later,
also a cleaved form (D2D3) lacking the amino-terminal uPA-binding domain D1 was discovered
in vitro in U937 cells (Høyer-Hansen et al., 1992) and also in vivo in transplanted murine
tumors (Solberg et al., 1994). Several enzymes (uPA, plasmin, and chymotrypsin) can cleave the
receptor at the linker region between domains 1 and 2 (Behrendt et al., 1991; Høyer-Hansen et
al., 1992; Høyer-Hansen et al., 1997b). The receptor cleavage by uPA occurs quite slowly in
solution, whereas on the cell surface the cleavage is highly accelerated (Høyer-Hansen et al.,
1997b). All of this suggests that the receptor cleavage is a negative feedback mechanism for
plasminogen activation on the cell surface. Both phosphatidylinositol-specific phospholipase C
and D are able to catalyze the cleavage of the whole receptor from the cell surface in vitro (Ploug
et al., 1991; Wilhelm et al., 1999), but the physiological enzyme functioning in vivo remains
unknown (see Figs. 3 and 4).
The primary function of uPAR originally appeared to be the localization of uPA and the
whole PA system onto specific areas on the cell surface. Through this function, uPAR
participates in localized proteolysis in wound healing, ovulation, angiogenesis, and cancer
invasion (Danø et al., 1994). Unexpectedly, the first knockout studies found no abnormalities in
uPAR-deficient mice: the mice were viable, healthy, and fertile (Dewerchin et al., 1996). Later on,
new, non-proteolytic functions for uPAR have been discovered, meaning that the function of
uPAR is no longer limited solely to the localization of plasminogen activation on the cell surface
(Danø et al., 1994; Blasi, 1997; Chapman, 1997; Blasi, 1999a; Blasi, 1999b; Preissner et al.,
2000; Waltz et al., 2000); it has other functions as well (see functions of uPAR below).
Soluble uPAR (suPAR)
The soluble form of the uPA receptor (suPAR) was first discovered in plasma from patients
with paroxysmal nocturnal hemoglobinuria (Ploug et al., 1992) and from ascitic fluid of ovarian
cancer patients (Pedersen et al., 1993). No uPA-ligand was bound to it, and it was also devoid of
the GPI anchor. Later, suPAR was also found in plasma from healthy individuals (Rønne et al.,
1995; Stephens et al., 1997), and the levels were quite stable at a median concentration of 1.2
ng/ml (range 0.8-1.7 ng/ml), with no correlation between age and suPAR (Stephens et al., 1997).
In addition to plasma/serum, suPAR also exists in cystic fluid of carcinoma patients (Wahlberg
et al., 1998) and more recently in their and in control urine samples (Sier et al., 1999). Such
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urine samples have been shown to contain uPAR fragments D2D3 and D1 in addition to the
full-length receptor (Sier et al., 1999; Sidenius et al., 2000), whereas only the full-length form of
uPAR is present in plasma samples (Sidenius et al., 2000). However, the physiological
mechanisms involved in the shedding of fragments or the entire receptor from the cell surface
have remained unknown (see Fig. 3).
In several different types of malignancies, elevated levels of serum/plasma suPAR have been
detected. For example, patients with non-small-cell lung cancer (Pappot et al., 1997), and cancer
of the breast (Stephens et al., 1997), colon (Stephens et al., 1999), ovary (Sier et al., 1998), and
prostate (Miyake et al., 1999), and with head and neck squamous cell carcinoma (Schmidt and
Hoppe, 1999) have significantly increased plasma suPAR levels. Furthermore, it has recently
been shown that suPAR levels correlate with survival prognosis, with those ovarian and colon
cancer patients showing high suPAR levels having a worse survival prognosis (Sier et al., 1998;
Stephens et al., 1999). The origin of suPAR in cancer patients' plasma has been unknown
(Brünner et al., 1999), and only recently was it demonstrated that mice carrying transplanted
human xenograft tumors have human suPAR in their plasma (Holst-Hansen et al., 1999),
suggesting that suPAR may be derived from tumor cells. The functions and importance of the
soluble receptors in vivo in body fluids are also largely unknown, although in vitro experiments
have shown that suPAR fragments may be involved in chemotaxis (Resnati et al., 1996; Fazioli
et al., 1997) (see below).
uPAR and signal transduction
There have been mechanical problems in understanding how uPAR can activate intracellular
signal transduction pathways, because it has no transmembrane or intracellular domain. One
possibility is that the activation of uPA, when bound to the receptor, induces the activation of
latent growth factors (like TGF-β and pro-HGF), which in turn can activate signal transduction
pathways (Besser et al., 1996; Koshelnick et al., 1999). However, in chemotaxis, current results
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suggest that no proteolytic activity of uPA is needed to induce the activation of p56/p59hck
kinases (Resnati et al., 1996). Furthermore, synthetic uPAR peptides, which carry a specific
epitope (see uPAR in chemotaxis, below), are able to induce chemotaxis in THP-1 cells and
activate the same tyrosine kinases (Fazioli et al., 1997). In addition, uPAR appears to be
physically associated with a number of other intracellular proteins, which participate in signal
transduction pathways (such as G-proteins, STAT proteins, and protein kinase C) (Koshelnick
et al., 1997; Dumler et al., 1998; Ossowski and Aguirre-Ghiso, 2000; Preissner et al., 2000). It
has therefore been suggested that a special transmembrane adaptor molecule exists, which can
mediate the signals between extracellular uPAR and intracellular kinase pathways (Resnati et al.,
1996; Blasi, 1999b). However, such an adaptor molecule has not been identified as yet, and it is
also possible that several of them exist, since not all signals induced by uPA-uPAR interaction
are uniform. The transmembrane glycoprotein 130 and β1-integrins are possible adaptor-
molecule candidates, because both these molecules are able to form complexes with uPAR and
activate intracellular signaling pathways (Aguirre-Ghiso et al., 1999; Koshelnick et al., 1999;
Yebra et al., 1999). In any case, the conformational change in uPAR appears to be the
prerequisite for inducing a signaling pathway (Ossowski and Aguirre-Ghiso, 2000).
Association of uPAR with vitronectin and integrins: functions in cell adhesion and
migration
The first reports of uPAR association with vitronectin and integrins came only a few years
after the discovery of uPAR. Bohuslav et al. (1995) showed that in human monocytes, uPAR is
one part of a receptor complex also including β2-integrins LFA-1 and Mac-1 and several protein
tyrosine kinases. This fact suggested functional cooperation between these molecules. Later, Xue
et al. (1997) observed that uPAR associates with β1 and β3 integrins also in cells of non-
hematopoietic origin, namely in fibrosarcoma cells. Furthermore, uPAR was able to form stable
complexes with integrins, which promoted cell-adhesion to vitronectin (Wei et al., 1996).
Recently, it was observed that uPAR interacts directly with integrins. The interaction site of
uPAR in Mac-1 was found to be in the CD11b subunit, and one peptide from this area disrupted
the association of uPAR with specific β1 and β2 integrins, and thus broadly impaired integrin
function (Simon et al., 2000).
uPAR interaction with integrins is also important in leukocyte migration. First, Bianchi et al.
(1996) showed that the stimulus likely to be associated with interaction between T-cells and
endothelial cells or ECM (co-clustering of the antigen receptor complex and β1 or β2 integrins)
induced the expression of uPAR in T-lymphocytes. Secondly, in uPAR-deficient mice, the β2-
integrin-dependent recruitment of leukocytes to the inflamed area is markedly reduced, and also
the removal of uPAR from the leukocyte surface blocks the β2-integrin-mediated leukocyte
adhesion to endothelium in vitro (May et al., 1998; Preissner et al., 2000).
Review of the Literature 25
                                                                                                                                                                 
The uPAR/vitronectin/PAI-1 interaction is a complex procedure that regulates cell adhesion
(Blasi, 1997). It has been demonstrated that vitronectin binding to uPAR induces specific uPAR-
dependent cell adhesion (Carriero et al., 1999). But as PAI-1 and uPAR have a common binding
site in vitronectin in the somatomedin B domain, they compete with each other (Deng et al.,
1996). An excess of PAI-1 will replace uPAR from vitronectin and detach cells from vitronectin
and inhibit cell migration, whereas an excess of uPA will neutralize PAI-1 and release adhesion-
promoting vitronectin, and therefore give the "go" signal for uPAR-vitronectin-dependent cell
migration (Deng et al., 1996). These findings can explain the clinical observations that high
tumor PAI-1 level is a poor prognostic marker (Schmitt et al., 1997), because PAI-1-mediated
release of cells from vitronectin can promote dissemination of these cells to distant sites, i.e.,
promote metastasis formation.
In addition to these non-proteolytic mechanisms such as uPAR binding to various integrins
as well as to vitronectin cell migration can also be promoted by uPAR-mediated proteolysis.
Especially in tumor cells, uPAR is localized at the leading edge of migrating cells. Therefore, by
binding uPA, uPAR locally enhances plasminogen activation and the formation of plasmin,
which in turn, can degrade ECM components. However, as other ligands (vitronectin, integrins,
PAI-1) are also present at the same sites, it is likely that the proteolytic and non-proteolytic cell
migration-promoting mechanisms of uPAR function in a tightly coordinated manner in vivo.
uPAR in chemotaxis
Gyetko et al. (1994) have found that monocyte chemotaxis in vitro is dependent on uPAR.
First, when monocytes were exposed to a chemotactic gradient, uPAR localized strongly to the
leading front of migrating cells. Secondly, monoclonal antibodies against uPAR inhibited the
monocyte chemotaxis induced by FMLP in Boyden chambers. Moreover, they noticed that the
function of uPAR was basically independent of active uPA, as inactivation of the catalytic activity
of uPA had no marked effect on monocyte chemotaxis (Gyetko et al., 1994). Recently the same
authors reported that in response to Pseudomonas aeruginosa infection, neutrophil recruitment
is reduced in uPAR knockout mice, but in uPA knockouts no difference occurred in recruitment
(Gyetko et al., 2000). In addition, their results suggested that recruitment of neutrophils requires
both β2-integrins and uPAR. Earlier they reported that uPA-deficient mice have an impaired
inflammatory response to pulmonary Cryptococcus neoformans infection (Gyetko et al., 1996).
However, uPAR was still functionally involved, as only the recruitment and migration of uPAR-
expressing leukocytes was affected in uPA -/- mice and not the recruitment of B-cells (those not
expressing uPAR) (Gyetko et al., 1996). These results suggested that uPA may play a role
through uPAR in chemotaxis. At the same time, Resnati et al. (1996) found that physiological
concentrations of uPA as well as of the aminoterminal fragment of uPA (ATF), which is capable
of binding to the receptor but has no proteolytic activity, induced chemotaxis in monocytoid
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THP-1 cells. However, the monoclonal antibody that blocks the binding of ATF to uPAR
inhibited the chemotactic activity of ATF. In addition, purified suPAR is capable of inducing
chemotaxis in the same cells, but the activity of suPAR in chemotaxis requires the cleavage of
the purified protein by chymotrypsin, at the same site where uPA can cleave uPAR. This
observation gave further support to the view that the interaction of uPA/uPAR is important in
chemotaxis, a view strengthened by the following experiments: Fazioli et al. (1997) tested the
chemotactic effect of several uPAR variants expressing different fragments of uPAR and found
that the chemotactic activity lies in the protease-sensitive region between domains 1 and 2, i.e., in
the same region efficiently cleaved by physiological concentrations of uPA. Furthermore, only
those synthetic peptides containing the sequence 88-92 of the uPAR linker region had
chemotactic activity, whereas peptides containing other parts of uPAR had no chemotactic
activity (see Fig. 4). In addition, in smooth-muscle cells, the cleaved form of suPAR and a
peptide covering the area between domains 1 and 2 induced chemotaxis and cytoskeleton
reorganization, which was accompanied by relocalization of uPAR, vitronectin receptor, and src
tyrosine kinase to the leading edge of migrating cells (Degryse et al., 1999). It therefore seems
that uPA cleavage is required for the conformational change in uPAR that uncovers its potent
chemotactic epitope. Although these are results only from in vitro experiments, it is tempting to
think that the uPAR fragments now found in cancer patients' urine and ascitic fluid samples may
have biological functions in vivo (Wahlberg et al., 1998; Sier et al., 1999). However, the detailed
amino-acid sequence of these in vivo fragments needs to be determined first, and the chemotactic
activity of the purified fragments obtained from ex vivo patient samples needs to be tested.
Fig. 4. Linker region of urokinase receptor. This diagram presents a protease-
sensitive region of uPAR between domains 1 and 2. Chemotactic activity of uPAR has
been reported to be located between aminoacids 88 and 92 (Fazioli et al., 1996)
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REGULATION OF PLASMINOGEN ACTIVATION CASCADE
The plasminogen activation system is regulated at many different levels. As described above,
several inhibitors (e.g., PAI-1 and -2) regulate the activity of plasminogen activators and in that
manner the whole activity of the PA cascade. This activity is also regulated by controlled
secretion of various components of the cascade, by conversion of proenzymes to active enzymes,
and by degradation or recycling of the components (e.g., recycling of the urokinase receptor). In
addition to this regulation at the protein level, the regulation naturally occurs also at the
transcriptional and translational level.
                                                                                                                                                                         
Regulation by hormones
In various cell types (both adherent and hematopoietic cells), glucocorticoids have been
reported to suppress uPA synthesis (Danø et al, 1985). The enhancer area in the uPA gene is
negatively regulated by dexamethasone. However, the mechanism is probably indirect, because
the glucocorticoid receptor fails to bind directly to the enhancer region (Besser et al., 1996). In
addition to their suppressive effects on uPA synthesis, glucocorticoids also seem to suppress
uPA activity. This is, in part, mediated by inhibitors, because dexamethasone, for example, can
increase PAI-1 expression in various cell types. The effect of glucocorticoids on tPA activity
depends on cell type. In some cell types, they seem to have no effect on tPA (e.g., in melanoma
cell lines), but in primary cultures of acute myeloid leukemia cells, glucocorticoids can either
stimulate or suppress tPA, depending on the patient from whom the cells came (Wilson et al,
1983a).
In addition to glucocorticoids, many other steroid hormones can also affect plasminogen
activator synthesis and activity: for instance, estrogen can increase uPA activity in rat uterus and
in human breast carcinoma cells, and androgens can induce plasminogen activator activity in
breast carcinoma cells. Other hormones as well, such as calcitonin, luteinizing hormone (LH),
and follicle-stimulating hormone (FSH), are able to either down- or up-regulate the plasminogen
activation cascade depending on cell type (Danø et al, 1985).
Regulation by cytokines
Inflammatory cells and endothelial cells produce various cytokines, such as interleukins (ILs),
tumor necrosis factor-α (TNF-α), and interferons. In addition, these same cells (monocyte-
macrophages, activated lymphocytes, and endothelial cells) are able to produce uPA.
Furthermore, in vitro studies have demonstrated that all these cytokines are able to increase uPA
activity (Hovi et al., 1981; van Hinsbergh et al., 1990; Gyetko et al., 1993). In monocytes, too,
the granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to increase
uPA activity (Hart et al. 1991). In addition to uPA, IL-1 and TNF-α can also induce the
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production of PAI-1 and –2, and similarly, in monocytoid cells, uPAR is upregulated by TNF-
α and interferon-γ (Lu et al., 1988). Furthermore, normal lymphocytes show no uPAR
expression on the cell surface, but various interleukins can induce uPAR expression in these
cells (Nykjær et al., 1994). In human myeloid cells, cytokines such as TNF-α prime myeloid
cells for uPA-mediated signals leading to cell adhesion (Waltz et al., 1993).
Regulation by growth factors
The plasminogen activation system interacts with growth factors in many ways. On the one
hand, uPA and/or plasmin can activate various latent growth factors (Taipale and Keski-Oja,
1997; Taipale et al., 1998) such as transforming growth factor-beta (TGF-β) and hepatocyte
growth factor (HGF), and on the other hand, these same growth factors can regulate the
expression of various components of the PA system (Laiho and Keski-Oja, 1989; Rifkin et al.,
1999).
Growth factors have high-affinity receptors on cell surfaces. By binding to the extracellular
part of the receptor, growth factors trigger intracellular signals via various kinase pathways. But
TGF-β, for example, is released from cells in an inactive form unable to bind the receptor. The
inactive latent form consists of TGF-β in complex with its binding protein (LTBP), and this
interaction inhibits the ligand-receptor interaction (Taipale et al., 1998). Plasmin, together with
other proteases, is able to release the TGF-β molecule from its propeptide protein and disrupt the
small latent TGF-β complex (Lyons et al., 1988). Therefore, it is able to play an important role in
TGF-β activation.
In normal physiology, TGF-β is a growth modulator which enhances ECM production and
suppresses ECM proteolysis. In various cell types, TGF-β induces PAI-1 expression and
suppresses the expression of both uPA and tPA (Laiho et al., 1987; Laiho and Keski-Oja,
1989). In addition, TGF-β enhances uPAR synthesis in various cell types, such as lung
carcinoma cells (Lund et al., 1991) and retinal pigment epithelial cells (Sirén et al., 1999). In
malignancy, TGF-β may act either as a tumor suppressor by inhibiting cell growth and
degradation of ECM, or as an oncogene because of its angiogenic effects. In addition, TGF-β is
able to induce many other growth factors, such as platelet-derived growth factor (PDGF), basic
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), which in turn
also have an effect on various components of the PA system. Both bFGF and HGF can enhance
PAI-1 expression (Wojta et al., 1999). In endothelial cells, in addition to increased PAI-1
expression, bFGF increases uPA activity (Mandriota and Pepper, 1997). Furthermore, uPA and
plasmin release VEGF and other growth factors from ECM (Taipale and Keski-Oja, 1997) and
in this manner promote angiogenesis. In endothelial cells, the binding of VEGF-B to its receptor
has also been shown to lead to increased expression of uPA and PAI-1 (Olofsson et al., 1998),
suggesting that VEGF-B may play a role in extracellular proteolysis and cell adhesion. Taken
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together, these reports confirm that several growth factors either directly induce or suppress the
synthesis of plasminogen activators or indirectly affect their activity by inducing or repressing
the expression of plasminogen activator inhibitors. In cancer, this regulation can be disrupted;
the synthesis and activation of various components of PA system may then occur in an
uncontrolled manner.
PLASMINOGEN ACTIVATION SYSTEM IN CANCER
The traditional view of the PA system in cancer was that tumor cells produce enhanced
amounts of plasminogen activators, mainly uPA, which in turn activate plasminogen to plasmin.
Plasmin then catalyzes the degradation of ECM proteins and in this manner, facilitates cancer
cell invasion into the tissues (Mignatti and Rifkin, 1993; Bell, 1996) (see Fig. 5). However,
because novel functions are being found for different components of the PA system, also the
traditional view has been broadening (Andreasen et al., 2000). Although uPA has been
suggested to be the main plasminogen activator in cancer--in melanoma and neuroblastoma--tPA
may play a role (Neuman et al., 1989; Bizik et al., 1993). Furthermore, that endothelial cells
produce a lot of tPA can be related to vasculature formation in cancer.
Both activators and inhibitors of the PA system as well as uPAR are widely expressed by
various tumor cell lines (Kwaan et al., 1991; Andreasen et al., 1997). Also in vivo, primary
tumors and metastases both express these same components in enhanced amounts (Bianchi et
al., 1994). In addition to tumor cells, also stromal cells and tumor-infiltrating macrophages can
produce several components of the PA system (Pyke et al., 1993). Indeed, it has been proposed
that tumor cells act in concert with stromal cells in cancer invasion (Johnsen et al., 1998). In this
manner, the synthesis of proteolytic factors can be distributed between neoplastic and non-
neoplastic cell types, and it is possible that tumor cells recruit and control stromal cells in order
to produce these factors (Danø et al., 1994; Danø et al., 1999). This view is strengthened by
results from in vivo studies; for example, in breast carcinoma, uPAR is expressed more often in
tumor-associated macrophages in the areas of infiltrating cancer cells than in the actual tumor
cells (Pyke et al., 1993).
Studies in the early eighties were already showing that the inhibition of uPA impaired tumor-
cell invasion in experimental tumor models (Ossowski and Reich, 1983). In addition,
enhancement of uPA expression increases the in vitro invasiveness of tumor cells. Systemic
analysis of tumor tissues and plasma samples of cancer patients confirms further the importance
of the PA system in cancer invasion (Andreasen et al., 1997). It has been demonstrated that the
expression of uPA is associated with unfavorable prognosis in several cancer types, such as
breast and colon carcinoma (Ganesh et al., 1994; Andreasen et al., 2000). Furthermore, uPA
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correlates with the histologic grade and with the metastatic potential of the carcinoma. In addition
to uPA, also high tumor antigen PAI-1 and uPAR levels and decreased PAI-2 levels are
associated with poor disease outcome (Schmitt et al., 1997; Stephens et al., 1998). However, as
the measurements of PA components in the tumor tissue are often quite laborious and also
difficult to standardize (Stephens et al., 1998), attempts have been made to correlate the levels of
uPA, uPAR, and PAI-1 in the circulation with prognosis. Circulating uPAR levels in cancer
patients have already been shown to associate with poor survival prognosis in colon carcinoma
and ovarian carcinoma patients (Sier et al., 1998; Stephens et al., 1999).
In addition to tumor cell invasion, the PA system may also participate in other cancer-related
processes, such as in hemostatic disorders often suffered by cancer patients (Carroll and Binder,
1999) and in angiogenesis (Carmeliet and Collen, 1998; Reijerkerk et al., 2000). Indeed, reports
have described severe bleeding disorders in cancer patients with normal platelet counts and other
fibrinolytic markers, but active uPA and plasmin generation in their circulation and production of
uPA by their tumor cells (Bennett et al., 1997). In angiogenesis, the uPA-mediated PA system
has also been shown to play an important role. uPA and plasmin can activate latent growth
factors (like HGF, TGF-β), which in turn can regulate the formation of new vessels (Carmeliet
and Collen, 1998) (Fig. 5). Furthermore, plasmin-activated matrix metalloproteinases stimulate
endothelial cell proliferation and migration (Werb et al., 1999). Vascular endothelial cell growth
factor (VEGF) upregulates uPA/uPAR expression in endothelial cells, and plasmin can release
VEGF from the ECM (Carmeliet and Collen, 1998). Moreover, angiostatin, which has potent
antiangiogenic activity, is a section of plasminogen, consisting of its kringles 1 to 4 (Reijerkerk
et al., 2000).
In cancer cell invasion, the PA system may also function in concert with other proteinases.
Many matrix metalloproteinases have also been related to tumor-cell invasion by their
degradation of ECM proteins (Blobel, 2000; Curran and Murray, 2000), and in MMP-2
deficient mice, tumor progression, for example, is significantly decreased (Itoh et al., 1998).
Plasmin’s activation of several metalloproteinases can facilitate cancer cell invasion through the
other proteinases (Fig. 5). Furthermore, as shown in wound-healing experiments in mice,
simultaneous inhibition of plasminogen and of a variety of matrix metalloproteinases totally
arrested wound healing, suggesting a functional overlap between these two systems which may
also have an effect on the tissue remodeling processes in cancer (Lund et al., 1999).
Because in vitro experiments have shown that cancer cell invasion can be quite efficiently
inhibited by antibodies against uPA or uPAR (Crowley et al., 1993; Reijerkerk et al., 2000),
many attempts have been made to develop for cancer patients similarly acting drugs for anti-
invasive therapy. The classic old proteinase inhibitors inhibit both uPA and tPA and may, in this
way, disturb fibrinolytic balance. Therefore, a need exists for selective uPA inhibitors or for
inhibitors inhibiting the binding of uPA to its receptor (Tressler et al., 1999). The uPA active-site
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inhibitor B-428 inhibits breast carcinoma invasion and metastasis in the in vitro matrigel model,
as well as in mice (Xing et al., 1997; Alonso et al., 1998). Furthermore, molecules inhibiting uPA
binding to the receptor (e.g., peptides antagonizing uPA-uPAR interaction) have been
demonstrated to inhibit angiogenesis and tumor metastasis formation in mice (Min et al., 1996;
Guo et al., 2000; Mishima et al., 2000). Although these experiments are encouraging, it remains
to be seen whether these molecules may be useful in clinical tumor therapy in the future.
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Fig. 5. Proteinases in cancer cell invasion. Cancer cell invasion is a complex process involving
several enzymes, growth factors, and matrix and membrane proteins. Invasive cells can secrete both
matrix metalloproteinases (MMPs) and serine proteases (plasmin), which also interact which each other.
Cancer cells can also recruit stromal cells to produce these enzymes. Growth factors are able to induce
the production of these enzymes and their inhibitors, but in addition, plasmin, for example, controls the
activation of certain growth factors. Furthermore, several inhibitors (PAI-1, TIMP) control the activity of
enzymes, and PAI-1 also mediates cell adhesion and migration pathways together with integrins,
vitronectin, and uPAR.
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PLASMINOGEN ACTIVATION IN LEUKEMIA
Components of the PA system in normal blood cells
Several types of leukocytes express various components of the PA system. For example,
uPAR and uPA are expressed by monocytes, macrophages, neutrophils, and myeloid precursors,
but not usually by lymphocytes (Wilson et al., 1983b; Miles and Plow, 1987; Wilson et al.,
1992; Plesner et al., 1994b; Jardi et al., 1996; Plesner et al., 1997; Mustjoki et al., 1999).
However, T-cells from HIV-positive patients express uPAR (Nykjaer et al., 1994), and
interleukin or PMA stimulation can also induce uPAR expression in normal lymphocytes
(Nykjaer et al., 1994). In addition, it has been recently reported that antibodies against uPAR
inhibit dendritic cell-induced T-cell activation, suggesting that uPAR may also play a role in
antigen-presenting cell/T-cell interaction (Woodhead et al., 2000). In thrombocytes and
erythrocytes no uPAR has been found, but our previous studies demonstrated that
megakaryocytes express uPAR on the cell surface in the bone marrow. Both tPA and uPA are
expressed by various types of leukocytes. Wilson and Francis (1987) have observed that the
type of plasminogen activator produced by leukocytes is a differentiation-linked property. In
normal bone-marrow cells, uPA was secreted by the more differentiated cells, whereas the more
primitive cells released tPA. tPA protein and mRNA have also been characterized in bone
marrow megakaryocytes (Jeanneau and Sultan, 1988; Brisson-Jeanneau et al., 1990).
Plasminogen activator inhibitors, PAI-1 and PAI-2, are also produced by blood cells. PAI-2 is
mostly expressed by monocytes but not by other leukocytes, whereas PAI-1 is released by
thrombocytes, and in addition, in normal bone marrow, PAI-1 mRNA has been found in
megakaryocytes (Alessi et al., 1994).
An active fibrinolytic system exists in normal human bone marrow (McWilliam et al., 1996).
In contrast to plasma, normal bone marrow has higher levels of active tPA, despite the inhibitors
PAI-1 and PAI-2. In addition, the levels of uPA, α2-antiplasmin, and tPA-PAI-1 complexes are
low, favoring fibrinolysis in the bone marrow (McWilliam et al., 1996). This tPA activity may be
necessary for removing fibrin deposits and ensuring sufficient blood flow through the bone
marrow.
Components of the PA system in leukemia
Similarly to normal leukocytes, leukemic cells were also found to produce plasminogen
activators into their growth medium (Wilson et al., 1983b; Tapiovaara et al., 1996). Leukemic
cells from AML patients produce quite different amounts of plasminogen activators into the
growth medium, but the amount produced has no correlation with the clinical severity of the
disease (Wilson et al 1983b). Leukemic cells are able to produce both uPA and tPA, whereas
normal granulocytes produce only uPA. Another interesting finding was that patients whose
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cells produce only tPA fail to respond to combination chemotherapy (Wilson et al., 1983b). As
later experiments showed that in healthy individuals more primitive leukocytes produce tPA, and
mature leukocytes produce uPA, the authors postulated that this may be the reason for the tPA
producers' poor response, as poor responses are more often seen in patients whose cells have
early-progenitor-type features (Wilson and Francis, 1987). Moreover, both plasminogen
activators and their inhibitors occur in higher amounts in leukemic cell homogenates from AML
patients than from ALL patients (Wada et al., 1993), and plasma uPA levels are also increased in
AML patients (Garcia Frade et al., 1992).
Studies describing the expression of uPAR on the leukemia cell surface have given somewhat
discrepant results. Plesner et al. (1994b) found uPAR to be expressed in bone marrow leukemic
cells in 12 of their 21 AML patients with FAB classes M2, M4, and M5, but not with FAB class
M1. No uPAR was found in lymphoblastic leukemia cells. A few years later, Jardi et al. (1996)
found uPAR to be expressed only on the surfaces of the most mature acute myeloid leukemias,
M3 and M5 leukemia, but in these groups the pattern was also heterogeneous. At the same time
as our observations (Mustjoki et al. 1999), Lanza et al. (1998) showed that leukemia cells from
all common AML FAB-groups (M0-M5) can have uPAR on their cell surfaces. Furthermore,
they described an AML subgroup (high uPAR positivity, chromosome 11 abnormalities, and
M5 FAB morphology) characterized by a more aggressive clinical course. uPAR mRNA
production of leukemic blast cells has been shown to be limited to FAB-classes M4 to M5
(Scherrer et al., 1999). In sum, all these studies agree that leukemic cells in lymphoid
malignancies do not express uPAR. Moreover, uPAR expression is related to malignancies of
myeloid origin, but among them the pattern is heterogeneous.
In vitro experiments with leukemia cell lines have also revealed that leukemia cells have an
enhanced capacity to activate the pro-uPA they produce, and mainly the active form of uPA is
found on the cell surface and in their growth medium; this differs from adherent tumor cells,
which produce only inactive pro-uPA (Stephens et al., 1988; Tapiovaara et al., 1991; Stephens et
al., 1992). This suggests that leukemic cells have an active proteolytic potential on their cell
surfaces. These results are also applicable in vivo. Tapiovaara et al. (1993) found active uPA in
the mononuclear cells of peripheral blood and bone marrow in patients with acute leukemia, but
not in control subjects or patients with chronic leukemia. No correlation appeared between the
lineage of leukemia and PA activity. However, Scherrer et al. (1999) found recently that
leukemic cells only from AML patients have uPA mRNA and produce active uPA protein,
whereas cells from ALL patients lack this ability. Active uPA has also been found in the
cerebrospinal fluid of acute leukemia patients (Akenami et al., 1996). In addition, in acute
myeloid leukemia marrow, the active form of uPA occurs, in contrast to normal bone marrow,
which shows mostly tPA activity (McWilliam et al., 1998). This uPA activity was suggested to
contribute to the severe hemorrhage occurring in AML patients (see below).
34 Review of the Literature
                                                                                                                                                                 
Plasmin formation plays an important role in normal blood coagulation and fibrinolysis.
Plasmin inhibitors in plasma (α2-macroglobulin and α2-antiplasmin) strictly control the plasmin
formation. In leukemia patients, the fibrinolytic balance is often disturbed, and patients have
severe bleeding diathesis. This bleeding diathesis is explained not only by thrombocytopenia,
since even with reasonable thrombocyte counts leukemia patients can experience severe
bleeding. In addition to thrombocytopenia, excessive fibrinolysis has been proposed as causing
some of these problems. This view has been strengthened by the finding that patients with
bleeding disorders have had free uPA in their plasma (Bennett et al., 1989). In addition, APL
patients with disseminated intravascular coagulation (DIC) have shown reduced plasma levels of
PAI-1 and increased levels of plasmin-α2-antiplasmin complexes and hypofibrinogenemia,
suggesting that the actual problem in DIC is excessive fibrinolysis rather than excessive
coagulation (Sakata et al., 1991; Fukao et al., 1992; Dombret et al., 1993; Dombret et al., 1995).
INTERCELLULAR ADHESION MOLECULES (ICAMs)
Structure and function of ICAMs
ICAMs belong to the immunoglobulin (Ig) superfamily. Humans have at least five of these
glycoproteins (ICAM-1 through -5), and they consist of various numbers of Ig domains:
ICAM-1 (CD54) and -3 (CD50) have five Ig domains, ICAM-2 (CD102) and -4 (Landsteiner-
Wiener antigen) have four, and ICAM-5 (telencephalin) nine Ig domains (Carlos and Harlan,
1994; Gahmberg, 1997; Gahmberg et al., 1997). In addition to Ig domains, all ICAMs also have
a single membrane-spanning domain and a short cytoplasmic portion. ICAM-1, -2, and -3 are
expressed by leukocytes, whereas ICAM-4 is found in erythrocytes and ICAM-5 in brain gray
matter (Gahmberg, 1997; Gahmberg et al., 1997). In addition, endothelial cells express ICAM-1
and -2.
ICAM 1 to 3 are important mediators of leukocyte adhesion; they act as ligands for the
leukocyte-specific β2-integrins (CD11/CD18). LFA-1 (CD11a/CD18) has been shown to bind
all these three different ICAMs, while Mac-1 (CD11b/CD18) binds only ICAM-1 and -2. In
addition, CD11d/CD18 can bind ICAM-3. The binding sites for the β2-integrins are located in
the ICAMs’ aminoterminal domain. Only ICAM-1 binds Mac-1 with its third domain
(Gahmberg, 1997; Gahmberg et al., 1997).
In addition to cell-surface forms, also circulating forms of these leukocyte ICAMs have been
described. Soluble ICAM-1 (sICAM-1) was first found in normal human serum and in
increased amounts in patients with leukocyte adhesion deficiency (Rothlein et al., 1991). Later,
sICAM-1 levels have been shown to be increased in several conditions, such as inflammation
and cancer (Banks et al., 1993; Gearing and Newman, 1993; Nash et al., 1996; Bloom et al.,
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1999; Khoury et al., 1999; McDonnel et al., 1999). The soluble molecule contains most of the
extracellular portion of ICAM-1, and it is also able to bind LFA-1 with high affinity (60 nM)
(Rothlein et al., 1991; Woska et al., 1998). However, the function of sICAM-1 in plasma is
unknown. Similarly to sICAM-1, soluble ICAM-3 (sICAM-3) was first found in human serum
(Martin et al., 1995; Pino-Otín et al., 1995) and in increased amounts in various pathological
conditions: in chronic inflammatory diseases (rheumatoid arthritis, multiple sclerosis, and
systemic lupus erythematosus) and malignancies (Martin et al., 1995; Pino-Otín et al., 1995;
Littler et al., 1997). Recently, it was shown that sICAM-3 can also bind LFA-1, but with much
lower affinity than sICAM-1 (Woska et al., 1998). Furthermore, sICAM-3 and -1 were
demonstrated to compete with each other in LFA-1 binding. As in the case of sICAM-1, the
biological function of sICAM-3 is unknown.
In response to inflammatory stimuli, leukocytes start to extravasate from the blood stream
through the endothelial cell layer and basement membrane into the extracellular matrix to the site
of inflammation (Carlos and Harlan, 1994). In this process, they first roll along the endothelial
cell layer. This rolling has been shown to be mediated by selectins and their olicosaccharide
ligands. After rolling, leukocytes attach firmly to the endothelial cell layer. Adherence is
mediated by β2-integrins, which become activated and begin to bind (Carlos and Harlan, 1994;
Gahmberg, 1997; Gahmberg et al., 1997). After this attachment, leukocytes need to penetrate
through endothelial-cell layers by squeezing themselves through intercellular junctions. Some
evidence exists that integrins are involved in this transmigration (Smith et al., 1988; Smith et al.,
1989), but the regulation of this process and the molecules participating in it are not yet known
in detail.  Supporting the theory of integrin involvement, it has been shown that neutrophils from
patients with leukocyte adhesion deficiency syndrome (an inherited defect in β2-integrins) are
unable to move across the endothelial cell layer (Smith et al., 1988). In addition, ICAM-1 and
LFA-1 are important in monocyte transmigration, as antibodies to these molecules inhibit the
transmigration of monocytes through the endothelial-cell layer (Mentzer et al., 1987; Te Velde et
al., 1987; Arnaout et al., 1988; Luscinskas et al., 1994; Takahashi et al., 1994; Kling et al., 1995;
Meerschaert and Furie, 1995). It has also been shown that PECAM-1 (CD31) is involved in
neutrophil and monocyte diapedesis through endothelial cells (Carlos and Harlan, 1994).
However, further studies are still needed to clarify the exact mechanisms of leukocyte
transmigration through endothelial cells and basement membranes.
ICAMs and leukemia
As ICAMs are widely expressed and have important functions in normal leukocytes, it has
been thought that they play an important role in leukemia cells as well. The actual functions of
ICAMs in leukemia cells are not known in detail, but it has been suggested that they may
participate in releasing blast cells from the bone marrow into the circulation, in homing blasts to
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various organs, and in aiding blast cells to communicate with each other. The expression of
adhesion molecules on the blast cell surface varies between leukemia types and also between
patients with the same type of leukemia. ICAM-1, CD11a, and CD18 are usually expressed both
in AML and in ALL blasts, but some patients in these groups have no expression at all on their
blast cells (Maio et al., 1990; Archimbaud et al., 1992; Reuss-Borst et al., 1992; Liesveld et al.,
1993; Raspadori et al., 1993; Reuss-Borst et al., 1995; Hirano et al., 1996; Kawada et al., 1996;
Mielcarek et al., 1997; Bruserud and Ulvestad, 1999; De Waele et al., 1999). In contrast, CD11b
is more commonly expressed in AML blasts than in ALL blasts (Reuss-Borst et al., 1995). In
B-cell chronic lymphocytic leukemia (B-CLL) ICAM-1, -2, and -3 are frequently expressed
(Molica et al., 1996; Vincent et al., 1996; Csanaky et al., 1997; Behr et al., 1998; Angelopoulou
et al., 1999). There have been attempts to find a correlation between blast cell expression of
adhesion molecules and clinical behavior of the disease, but the results have been quite
discrepant. Some studies report no correlation between blast cell expression of ICAMs and
clinical behavior (Archimbaud et al., 1992; Kawada et al., 1996). However, Mielcarek et al.
(1997) showed in childhood ALL a positive correlation between low ICAM-1 expression and
high peripheral leukocyte count and central nervous system involvement. ICAM-1 seemed to be
a favorable prognostic factor, but not independent. In adult AML, LFA-1 expression has been
shown to correlate with splenomegaly and resistance to chemotherapy and therefore to shorter
survival (Kawada et al., 1996).
To our knowledge, the circulating form only of ICAM-1 has been studied in leukemia thus
far, and is increased in childhood ALL and also in adult AML and ALL (Pui et al., 1993;
Sudhoff et al., 1996). No correlation exists between the white blood cell count and sICAM-1
levels, sICAM-1 level the correlation with the clinical behavior of leukemia is weak (Pui et al.,
1993; Sudhoff et al., 1996). However, in childhood Hodgkin's disease and adult B-CLL,
sICAM-1 levels correlate with disease stage and also with frequency of relapse (Pui et al., 1993;
Christiansen et al., 1994). In remission, the levels were normal in childhood malignancies. In
sum, the number of studies is still small, and more information is needed to clarify the overall
prognostic impact of adhesion molecules in leukemia.
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AIMS AND OUTLINE OF THE PRESENT STUDY
The active processes of pericellular proteolysis and cell adhesion and invasion are central in
tumor invasion. The importance of the plasminogen activation system and especially the roles of
uPA and uPAR are well established in solid tumors, but in hematopoietic malignancies these
were less clear.
In promyelocytic leukemia, Tapiovaara et al. (1994) found that retinoid acid (RA), which is
used as a differentiation therapy for APL patients, transiently increases uPA activity in
promyelocytic cells. However, the effects of RA on the plasmin formation were still unknown.
Furthermore, some reports suggested that RA together with interferons could be a more efficient
differentiation therapy in cancer. Therefore, we aimed to study the effects of RA together with
interferons on the activation of plasminogen and on the formation of plasmin in APL cells in
culture. RA treatment may result in a severe complication called retinoic acid syndrome
characterized by fever, leukocytosis, and pulmonary infiltrations. APL patients with this
syndrome have a shorter survival than do patients without the syndrome (De Botton et al., 1998).
However, the actual pathophysiological mechanisms behind the syndrome are unclear.
Therefore, we chose to evaluate the effects of RA on the invasion capacity of APL cells in three-
dimensional culture. Because the invasion mechanisms of leukemia cells are, overall, quite
poorly understood, we also chose to evaluate the blast cell extravasation in the same organotypic
model, and the involvement of various adhesion molecules.
The presence of the soluble urokinase receptor in plasma was first described by Ploug et al.
(1992). In 1997, Stephens et al. reported that some cancer patients show increased serum
suPAR levels. In leukemia this had not been studied, and the characterization of the other
components of the PA system in ex vivo leukemia cells had also been inconclusive. Therefore,
we chose to evaluate uPA and uPAR expression on the blast cell surface and in the plasma
samples of leukemia patients at diagnosis, and to study their correlation with the type and clinical
behavior of their leukemias. Because results from these studies suggested that AML patients
with high suPAR levels at diagnosis had a poor response to chemotherapy, we aimed to further
analyze the behavior of suPAR during chemotherapy, and to examine whether it could serve as a
marker for relapse in leukemia. Furthermore, we chose to study the origin and cleavage of
suPAR in leukemia patients, because uPAR fragments are able to induce a chemotactic effect in
vitro (Resnati et al., 1996, Fazioli et al., 1997). In addition, the cellular source of suPAR in
plasma samples of healthy individuals was still unclear. Therefore, we also studied the release of
suPAR by various cell types, and the influence of cell-cell contact on such release.
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MATERIALS AND METHODS
Patient samples
Blood samples
Blood samples were obtained at the time of diagnostic sampling from patients referred with a suspicion of
acute leukemia before any cytoreductive treatment. Altogether, samples from 135 adult patients with acute
leukemia and 55 patients with other hematological disorders were enrolled into this study. In addition, from 58 of
these 135 acute leukemia patients, follow-up samples were obtained during chemotherapy at 5, 14, 28, and 56
days after start of therapy. Samples from 40 healthy volunteers served as controls. All samples were collected at
the Helsinki University Central Hospital during the years 1996 to 2000. The study protocol was approved by the
local ethics committee.
Blood samples were drawn into EDTA tubes and kept on ice before plasma separation. Plasma was separated
within 2 hours by centrifugation for 30 min at 4°C at 1800 x g and stored frozen in aliquots at -70°C until assay.
The mononuclear cell fraction was separated with Ficoll-Hypaque centrifugation. In leukemia patients, most of
the mononuclear cells were tumor cells. The white blood cell (WBC) count and percentage of blast cells were
obtained from simultaneous routine tests. Tumor-cell count in the circulation was determined as percentage of
blast cells x white blood-cell count.
Urine samples
Urine samples were collected during the chemotherapy at days 0, 5, 14, 28, and 56 days after start of therapy
from 58 patients with acute leukemia. Samples were centrifuged at 4°C at 1800 x g for 10 min and stored frozen
in aliquots at -70°C before assay. Urine samples from 30 healthy controls were treated similarly.
Creatinine content of the urine samples was measured by the Jaffé method according to manufacturer's
instructions (Boehringer Mannheim) with a Hitachi 917 analyzer. Urinary suPAR levels were normalized for the
dilution factor based on creatinine values as earlier described (Sier et al., 1999). Ratios of uPAR/creatinine were
expressed as ng/ml uPAR divided by mg/dl creatinine.
Bone marrow samples
Bone-marrow aspirates were collected from 15 patients with acute leukemia, from 6 patients with other
hematological disorders, and from 5 healthy bone-marrow donors. Aspirates were collected into EDTA tubes, and
plasma was separated by centrifugation for 30 min at 4°C at 1800 x g and stored frozen in aliquots at -70°C.
Patient diagnoses
The diagnoses were based on morphological, cytochemical, cytogenetic, and cell-surface markers. Acute
myeloid leukemia (AML) was diagnosed in 92 of these 135 acute leukemia patients [French-American-British
(FAB) classes: M0: 8, M1: 13, M2: 31, M3: 5, M4: 17, M5: 9, M7: one, NC (not classified): 2, and 6
secondary leukemias] and acute lymphoid leukemia (ALL) in 35 patients (immunophenotypic classes: cALL: 25,
T-ALL: 6, pre-pre-B-ALL: 3 and one Burkitt lymphoma). Nine patients had a hybrid phenotype: both lymphoid
and myeloid markers were found on the cell surface. In addition, 55 patients with other hematological disorders
were included in the study: 18 patients with chronic myeloid leukemia (CML), 2 with chronic lymphocytic
leukemia, 4 with myeloma, 2 with idiopathic thrombocytopenia (ITP), 5 with aplastic anemia, 8 with
myelodysplastic syndrome (MDS), 2 with hairy-cell leukemia, one with lymphoma, one with heavy-chain
disease, one with chloroma, one with low-grade B-cell disorder, one with monocytosis NUD, one with
myelofibrosis, and 8 with reactive cytopenia (2 drug-induced, 4 due to infection, one due to systemic lupus
erythematosus, and one developed ALL later).
Treatment of patients with acute leukemia
Patients with AML were treated with high-dose combination chemotherapy containing idarubicin, cytarabine,
thioguanine, mitoxantrone, etoposide, and amsacrine according to the Finnish Leukemia Group protocol (Elonen
et al., 1997). Elderly patients were treated with reduced doses according to established guidelines. Patients with
ALL were treated according to the Finnish Leukemia Group protocol ALL94 consisting of cycles of high doses
of mitoxantrone, cytarabine, etoposide, daunorubicin, vincristine, asparaginase, methotrexate, teniposide,
doxorubicin, cyclophosphamide, mercaptopurine, carmustine, prednisone, and dexamethasone (Elonen et al.,
1998).
Response to therapy
The observation period for these patients varied from 6 months to 4 years. All were treated with ≥three cycles
of chemotherapy, unless they died. Their response to therapy was evaluated according to routine clinical practice.
AML patients were divided into two categories: A) patients with good response to chemotherapy: complete
remission with one to two cycles of chemotherapy, and no relapse within 6 months, B) patients with poor
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response to chemotherapy: residual disease after two cycles of chemotherapy or relapsed during therapy within 6
months.
Cell culturing
General cell cultures
Cell culturing was performed in a humidified 5% CO2 atmosphere at +37°C. Cells were grown in RPMI-
1640 in the presence of 10% fetal bovine serum (FBS) (GibcoBRL, Karlsruhe, Germany) containing 2 mM
glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin, unless otherwise indicated. The promyelocytic
NB4 cell line was kindly provided by Dr. Michel Lanotte (INSERM, Paris, France). It was derived from the bone
marrow of an acute promyelocytic leukemia (APL) patient in relapse, and carries the t(15;17) translocation
characteristic of APL cells (Lanotte et al., 1991). Other non-adherent hematopoietic cell lines used were U937,
Jurkat, KG1, RC2A, THP-1, HL60, and Molt from the American Type Culture Collection (ATCC) (Rockville,
MD). Human microvascular endothelial cells (HMEC-1) (Ades et al., 1992) were a kind gift from Dr. T.J.
Lawley (Emory University School of Medicine, Atlanta, GA). Human umbilical vein endothelial cells (HUVEC)
were isolated and grown in endothelial cell growth medium (PromoCell, Heidelberg, Germany).
In addition to normal culture plates, cells were also co-cultured in Transwell chambers (Costar, Corning, NY)
in order to have a shared growth medium without cell-cell contacts.
Organotypic model for vessel wall
Collagen type I was purified from rat tail tendons as earlier described (Elsdale and Bard, 1972). Collagen gels
were prepared by diluting purified collagen in RPMI medium containing 10% FBS, 2 mM glutamine, 100 IU/ml
penicillin, 100 µg/ml streptomycin, to achieve 0.6 mg/ml collagen in the final concentration. This solution, 0.4
ml per well, was pipetted into 48-well cell culture cluster plates (Costar, Cambridge, MA), and gels were allowed
to form for 30 min at +37˚C. Endothelial cells (80 000 cells in 0.4 ml of growth medium) were seeded on the
collagen gels and left to form monolayers overnight at +37˚C. Next morning, the growth medium was removed,
and freshly isolated blood mononuclear cells or leukemia cells were added (0.2 million cells/0.4 ml of growth
medium) on top of the endothelial cells. Monoclonal antibodies (20 µg/ml) or purified proteins were either
included in the growth medium at the same time as mononuclear cells were added, or endothelial cells were
preincubated with the antibodies for 30 min at +37˚C, before addition of the mononuclear cells. Adherence and
invasion of blood cells through the endothelial cell layer into the collagen matrix was monitored by light
microscopy. After 1 to 3 days of culture, the collagen rafts were carefully detached from the wells and fixed with
10% formaldehyde. After fixation, the rafts were processed as normal tissue samples, and before casting in
paraffin, they were cut vertically to reveal the cross section of the collagen rafts. Sections of 4 to 6 µm were cut
from the paraffin blocks and stained with hematoxylin and eosin (HE) for histological evaluation.
Invasion of the blood cells was studied in HE-stained sections under light microscopy. The number of invaded
cells in the collagen matrix per x 20 high-power field was counted in four different areas of each section and from
three different sections of each sample. The extent of invasion was determined as percentage of invaded cells
compared to sections of samples treated with control antibody.
Cell lysates
Cells were lysed in phosphate-buffered saline (PBS), pH 7.4, containing 1% Triton X-100 and protease
inhibitors (Complete™; Boehringer Mannheim, Mannheim, Germany). The lysates were centrifuged at 4°C at 14
000 x g for 10 min and the supernatants stored at -70°C until assay. Total protein was determined by the BCA
protein assay kit (Pierce, Rockford, IL).
Elution of uPA and plasmin from the cell surface
To determine the amount of cell-bound uPA activity, the cells were first washed twice with Dulbecco's
balanced salt solution containing 0.2% BSA (DBSA) and then eluted with acid glycine (20 mM glycine, 100
mM NaCl, pH 3.0) (Stoppelli et al., 1986). The acid glycine fraction was neutralized with 1 M Tris-HCl, pH
8.0. To determine the capacity to activate exogenously added plasminogen to plasmin, the cells were suspended
in plasminogen-depleted growth medium, and human plasminogen (50 µg/ml) was added (Tapiovaara et al.,
1991). Plasmin generation was allowed to proceed for 30 min at 37°C, after which cells were washed twice with
DBSA. Cells without incubation with plasminogen served as negative controls. Cell-bound plasmin was eluted
with 10 mM tranexamic acid (Kabi Pharmacia, Stockholm, Sweden) in DBSA (200 µl per 106 cells) for 10
minutes at room temperature. The eluates were then ready for enzymatic assays.
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Antibodies and molecular probes
Antibodies against different members of the PA system
The following antibodies were used: monoclonal antibodies against human uPAR R2, R3, R4, and R5
recognizing different domains of uPAR molecule (R2 and R4 react with the carboxyterminal domain D3 of
uPAR, and R3 and R5 with the aminoterminal domain D1), these kindly provided by Dr. Gunilla Høyer-Hansen,
Finsen Laboratory, Copenhagen, Denmark; polyclonal rabbit anti-human uPAR (Finsen Laboratory),
monoclonal anti-human uPAR (American Diagnostica, Greenwich, CT; #3936), polyclonal rabbit anti-human
uPA (American Diagnostica, #389), monoclonal anti-human uPA clone 12 (Finsen Laboratory), and polyclonal
goat anti-human tPA (American Diagnostica; #387).
Antibodies against adhesion molecules
The monoclonal antibodies were UHP cocktail (ICAM-1) (Tiisala et al., 1994), LB2 (ICAM-1) (Patarroyo et
al., 1987), TS 1/22 (CD11a) (Sanchez-Madrid et al., 1982), 7E4 (CD18) (Nortamo et al., 1988), BR7 (ICAM-2)
(Xie et al., 1995), CBRIC2/2 (ICAM-2) (Bender Medsystems, Vienna, Austria), and BR1 (ICAM-3).
Leukocyte and control antibodies
The monoclonal antibodies were: anti-CD68-recognizing monocyte-macrophages (KP1, DAKO, Glostrup,
Denmark), anti-CD3-recognizing T lymphocytes (DAKO), X63 (mouse IgG) (ATCC), anti-human cytokeratin
(DAKO, #M0630), anti-human biotin (DAKO, #M0743), and normal mouse or rabbit IgG (R&D systems,
Abingdon, UK; #MAB002/#AB105C).
Molecular probes
The cDNA clone for uPA (fragment BamHI) was obtained from ATCC. The cDNA clones for the uPAR
(fragment SphI SacI) (Roldan et al., 1990), PAI-1 (fragment BamHI) (Andreasen et al., 1986), and GAPDH
(fragment PstI) (Fort et al., 1985) were kindly provided by Dr. Jens Eriksen and Dr. Leif Lund (Finsen
Laboratory). The probes were labeled with digoxigenin (DIG) coupled to dUTP by a DIG random primed DNA
labeling kit (Boehringer Mannheim; cat. no. 1175 033) according to the manufacturer's instructions.
Other reagents
Effectors
13-trans retinoic acid (Tretinoin) was kindly provided by F. Hoffman-La Roche Ltd, Basel, Switzerland. The
stock solutions were dissolved in ethanol, and the concentration used in cell cultures was 1 µM. Interferons α
and γ were a kind gift from Drs. Kari Cantell and Ilkka Julkunen of the National Public Health Institute,
Helsinki, Finland (Sareneva et al., 1994, 1995). They were dissolved in RPMI-1640, and the concentration used
in cell cultures was 1000 IU/ml. Dexamethasone (Sigma, St. Louis, MO; #D8893) was dissolved in ethanol, and
the concentration used was 100 nM. Phorbol 12-myristate 13-acetate (PMA) was also dissolved in ethanol and
used at a concentration of 50 nM.
Plasminogen
Plasminogen was purified from precleared citrated plasma according to Deutsch and Mertz (1970). In brief,
plasma was run through a Lysine-Sepharose column in the presence of several protease inhibitors to inhibit the
activation of plasminogen to plasmin. Lysine-bound plasminogen was eluted from the column with the
aminocaproic acid, after which the fractions with high protein concentration were re-run through the column and
eluted similarly with the aminocaproic acid. Finally, eluted fractions were dialyzed, and protein concentration was
determined with the BCA protein assay kit; the purity of the protein was determined by running the samples in
8% SDS-PAGE.
Collagen type I
Collagen type I was purified from rat-tail tendons according to an established method (Elsdale and Bard,
1972). In brief, tendons were purified and dissolved in 10 mM HCl from which collagen was precipitated with
NaCl. It was then further dissolved in 2.5 mM HCl, with extra salt removed by dialysis. The final protein
concentration was measured with the BCA protein assay kit (Pierce, Rockford, IL) and was usually 1-1.5 mg/ml.
Production and purification of sICAM-1
A soluble form of ICAM-1 (sICAM-1) was purified as described by Hedman et al. (Hedman et al., 1992). In
short, sICAM-1 protein was produced by CHO cells, which were transfected with a fusion cDNA coding the
extracellular part of ICAM-1 and a part of IgG heavy chain. Transfected cells produced the fusion protein into the
growth medium, and from the growth medium, it was purified on a protein Sepharose A column, which bound
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the Fc part of the protein. Bound protein was eluted with 0.1 M glycine, pH 3.0, from the columns. Eluted
fractions were concentrated, and the buffer was changed to PBS by means of Centricon-30 tubes (Millipore,
Bedford, MA). The purity of the fusion protein fraction was evaluated by 8% SDS-PAGE. Protein concentration
was determined by the BCA protein assay kit (Pierce).
Enzyme-linked immunosorbent assays (ELISAs) and other microwell plate assays
Assay of soluble uPAR and uPAR in cell lysates
The ELISA for suPAR has been described in detail (Stephens et al. 1997). In brief, immunoplates were
coated overnight with purified polyclonal anti-human uPAR antibodies. The wells were blocked with SuperBlock
solution (Pierce), and after this blocking, the wells were rinsed with PBS-Tween 20. After washing, the wells
were incubated with standard dilutions of purified recombinant suPAR or with 1:10 dilutions of plasma and urine
samples made in a sample dilution buffer (7 mM KH2PO4, 40 mM Na2HPO4, pH 7.4, 0.1 M NaCl, 2 mM
KCl, 10 g/L BSA, and 1 g/L Tween 20). From the cell lysates, protein concentrations were first determined, and
then a volume equal to 20 µg of protein was placed in each well. After antigen binding, the wells were rinsed,
and then plates were incubated with a mixture of three monoclonal anti-human uPAR antibodies (R2, R3, and
R5), followed by a rabbit antimouse immunoglobulins-alkaline phosphatase conjugate. After washing, a p-
nitrophenyl phosphate substrate solution was added, and a color reaction was allowed to develop at room
temperature. The absorbances were read in a Multiscan MCC/340 plate-reader (Labsystems, Helsinki, Finland) at
405 nm. Each sample was tested also without specific monoclonal antibodies, and a few plasma samples gave a
low positive reaction. These samples were not included in the analysis and in the tables are marked as reactive
(R). Interassay variation for the samples was <10%, and the lower detection limit of this assay was 0.03 ng/ml.
Immunocapture assay for plasminogen activators
uPA and tPA activities were assayed by a microimmunocapture assay (Stephens et al., 1987). It measures
inactive proenzymes by activating them to active two-chain forms. It does not measure plasminogen activators in
complexes with inhibitors. Briefly, samples were bound in duplicate or triplicate to microwell plates coated with
10 µg/ml of rabbit IgG to human uPA (American Diagnostica, Greenwich, CT; #389) or goat IgG to human
tPA (American Diagnostica; #387). After binding, the wells were washed with PBS + 0.05% Tween 20, and then
human plasminogen was added. Plasmin formed by antibody-bound activators was measured by its thioesterase
activity on Z-lysine thiobenzyl ester (Peninsula Laboratories, Belmont, CA). The absorbances were read in a
Labsystems Multiscan MCC/340 plate-reader at 405 nm. Standard dilutions of purified human urokinase
(American Diagnostica; #124) and human tPA (American Diagnostica; # 116) served for quantitation of
enzymatic activity (0 to 1.0 IU/ml). The absorbance curve was linear between the values 0.1 to 1.0. The lower
detection limit of the assay for uPA and tPA is 0.02-0.04 IU/ml.
Assay of eluted plasmin
Eluted plasmin samples (50 µl) were pipetted in duplicate in microwell plates, and plasmin was measured by
its thioesterase activity as described above for the immunocapture assay. Standard dilutions of human plasmin
(Kabi Diagnostica) were used for quantitation of enzymatic activity.
Assay of uPA antigen
Plasma samples were assayed by an ELISA method according to the manufacturer's instructions (Monozyme,
Hørsholm, Denmark). This determines active and inactive (uPA-PAI-1-complexes) forms of uPA antigen. The
lower detection limit of the ELISA kit is 25 pg/ml of uPA.
Analysis of sICAM-1 and -2
Soluble ICAMs were assayed from plasma samples by ELISA methods. The human sICAM-1 immunoassay
kit came from BioSource International (Camarillo, CA), and the human sICAM-2 ELISA kit from Bender
MedSystems. The lower detection limits of the ELISA kits were 0.04 ng/ml of sICAM-1 and 0.46 U/ml of
sICAM-2.
Other immunological methods
Immunostaining of cell surface uPA, uPAR, and adhesion molecules by fluorescence-activated cell sorter
(FACS)
For FACS analysis, the cell samples (1x106 cells/ml) were collected, and the cell suspension was centrifuged
for 10 min at 1000 x g. The cells were washed with PBS containing 1% of FBS (PBS-FBS) and resuspended
after centrifugation in 50 µl of primary monoclonal or polyclonal antibody (conc. 10-50 µg/ml) (antibodies
described above). The cells were incubated in the presence of IgG for 30 min on ice, after which they were washed
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twice with PBS-FBS and resuspended in 100 µl of fluorescein isothiocyanate (FITC) -conjugated rabbit anti-
mouse IgG or swine anti-rabbit IgG (DAKO, Copenhagen, Denmark) diluted 1:50 in dilution buffer. After 30
min on ice, the cells were washed twice with PBS-FΒS and resuspended in 300 µl of PBS on ice; 10 000 cells
were analyzed with a FACScan IV (Becton Dickinson, Mountain View, CA). In the case of patient samples,
blast cell populations were detected based on their forward- and sidescatter properties, and only that population
was included in the analysis.
Immunoprecipitation and immunoblotting
Urine, plasma, and cell lysate samples were immunoprecipitated with biotinylated R2 and R3 monoclonal
antibodies (Finsen Laboratory) prebound to immobilized streptavidin (Boehringer Mannheim) (Sidenius et al.,
2000). These antibodies recognize different domains of uPAR: R2 reacts with the carboxyterminal domain D3 of
uPAR, and R3 with the aminoterminal domain D1. Immunoprecipitated proteins were fractionated by 12% SDS-
PAGE under non-reducing conditions. The proteins were transferred to nitrocellulose membranes and detected
with polyclonal rabbit anti-uPAR IgG, with chemiluminescent visualization of the complexes (SuperSignal
Ultra, Pierce).
Immunohistochemistry
A Ventana automated slidestainer for immunohistochemistry (Ventana Medical Systems, Tucson, AZ) was
used for staining the 4 µm paraffin sections. Detection was based on an avidin-peroxidase method using
biotinylated secondary antibodies. Counterstaining was done with hematoxylin, and bluing reagent (0.1M
lithium carbonate in 0.5 M sodium carbonate) served as the post-counterstain.
Immunofluorescence
Cells were grown on glass coverslips in multi-well culture plates. After culturing, the plates were transferred
onto ice, and the coverslips were washed twice with DBSA. After the washing, primary antibodies were added to
the coverslips and incubated for 30 min on ice, after which the cells were washed again. Before secondary
antibody addition, cells were fixed with ice-cold methanol for 15 min at -20°C followed by thorough washing and
then incubated with secondary FITC-conjugated antibodies (Myöhänen et al., 1993). At the end, cells were
washed again, and coverslips were mounted on object classes.
RNA extraction and Northern analysis
RNA extraction was done according to the method of Chomczynski and Sacchi (1987): 1x107 cells were
lysed in solution D containing guanidium thiocyanate, sodium citrate, sarkosyl, and 2-mercaptoethanol, and the
RNA phase was separated with a phenol and chloroform-isoamyl alcohol solution. The RNA isolated was
quantitated with a spectrophotometer, and those samples containing the same amount of mRNA (20 µg) were
size fractionated in 1% agarose gels and transferred to a Hybond N nylon membrane (Amersham,
Buckinghamshire, England). Prehybridizations and hybridizations were performed in a solution containing
formamide, standard saline citrate (SSC), N-laurosyl sarkosine, sodium dodecyl sulphate (SDS), and blocking
solution (Boehringer Mannheim). The hybridization was carried out overnight, and after that the filters were
washed twice at +42°C with 0.5 x SSC and 0.5 x SDS and then twice at +68°C. The detection was done by use
of alkaline phosphatase conjugated anti-digoxigenin (DIG) antibodies. Luminescent reactions from filters were
exposed to X-ray films. The X-ray films were scanned, and the relative intensities were determined in comparison
with the glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) signal from the same filter.
Zymography
Plasma, growth media, and cell lysate samples were electrophoresed on 10% polyacrylamide SDS-PAGE
gels, which were supplemented with plasminogen (10 µg/ml) and dry nonfat milk as a source of casein (Granelli-
Piperno and Reich, 1978). After electrophoresis, the gels were washed twice with 2.5% Triton X-100 and
incubated in 10 mM CaCl2, 50 mM Tris (pH 7.5) for 24 to 72 hours at 37°C. The gels were then stained with
Coomassie blue, after which clear bands were seen in the areas of proteolytic activity against the blue background
staining. Purified human uPA and tPA (American Diagnostica) served as positive controls.
Statistical analysis
The following tests were used for comparison of the results: Student's unpaired, paired, and one-group t-tests,
the Mann-Whitney U-test, and Chi-square test. The correlation coefficients r and Rho were calculated according to
Pearson and Spearman Rank Correlation tests. Results were considered significant when p≤0.05.
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RESULTS
Enhanced plasminogen activation and plasmin formation by retinoids and
interferons in acute promyelocytic leukemia cells (I)
Patients with acute promyelocytic leukemia (APL) are treated with retinoic acid (RA) in
addition to conventional chemotherapy. RA induces the differentiation of promyelocytic
leukemia cells in vitro and in vivo, and it also reduces the bleeding tendency characteristic of
APL patients. Severe side-effects (leukocytosis, pulmonary infiltrations, and respiratory distress
syndrome) sometimes caused by the RA treatment are called the retinoic acid syndrome. These
side-effects are relieved by dexamethasone administration, but occasionally the syndrome has a
fatal outcome. The plasminogen activation system and plasmin formation play an important role
in fibrinolysis, and it has also been suggested that plasminogen activation can affect the
fibrinolytic balance in leukemia patients. Tapiovaara et al. (1994) showed earlier that RA
treatment induces a transient uPA increase in promyelocytic NB4 cells. However, the actual
formation of plasmin by promyelocytic leukemia cells had not been studied, and also the RA’s
effect on it was unknown. Furthermore, other in vitro studies have suggested that interferons and
retinoids may have combined effect on cell differentiation. Therefore, we chose to analyze the
activation of plasminogen to plasmin in promyelocytic cells and the effects of retinoids,
interferons, and dexamethasone on the plasminogen activation cascade. We used the
promyelocytic NB4 cell line as a model for acute promyelocytic leukemia and treated NB4 cells
with RA to induce differentiation. At the various time points (12, 24, and 48 hours) we collected
samples of growth medium and cell surface eluates and extracted mRNA from these cells.
Components of the PA system (uPA, uPAR, and PAI-1) were analyzed with specific ELISAs,
FACS analysis, and Northern blotting.
RA enhances transient uPA production and plasmin formation
As earlier observed (Tapiovaara et al., 1994), we, too, noticed that RA induced transient uPA
production in promyelocytic NB4 cells. The elevation was evident in mRNA level at 10 hours,
and at 24 hours the uPA mRNA level had already fallen to its basal level. On the cell surface and
in the growth medium, uPA protein levels rose for to 24 hours, this increase being more
pronounced in secreted uPA than in cell-bound uPA. Thereafter, uPA protein levels started to
fall again, and after 48 hours of treatment, less uPA was seen on the surface of RA-treated cells
that on control-treated cells. Our results also indicated that uPA induction led to the activation of
plasminogen on the NB4 cell surface. The generation of plasmin followed closely the induction
of uPA, with the highest cell-surface plasmin levels detected at 24 hours. After 48 hours of RA
treatment, plasmin levels fell below their basal level.
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Combined effects of RA and interferons or dexamethasone on the plasminogen activation
cascade
In contrast to RA, in NB4 cells, neither interferon α nor γ had any effect on the plasminogen
activation cascade. Yet, when either of these two interferons was combined with RA, more
pronounced induction of uPA appeared both in the mRNA level and in protein level. In addition,
a similar effect was seen in plasmin formation on the cell surface. This suggests that in
promyelocytic cells, RA and interferons have a synergistic effect on plasminogen activation.
We also studied the effect of dexamethasone on the PA system in promyelocytic cells. When
used alone, dexamethasone had no significant effect on the production of uPA or on plasmin
formation. When dexamethasone was added together with RA, it suppressed the effect of RA,
and neither cell surface induction of uPA nor induction of plasmin formation was any longer
observed.
Increase in levels of uPAR and PAI-1 after uPA induction
Because uPAR and PAI-1 are closely related to cell adhesion and migration, it was of interest
to study the effects of RA and interferons on uPAR and PAI-1 expression. In contrast to uPA
mRNA levels, for which a transient increase with RA treatment was evident at 10 hours, uPAR
and PAI-1 mRNA levels increased more markedly only after 21 hours of RA treatment, and
these levels continued to rise for up to 46 hours. The interferons potentiated especially the effect
of RA on the induction of PAI-1 expression, and a slight increase was also observable in uPAR
expression. Alone, interferons had no marked effect on uPAR or PAI-1 expression.
It is noteworthy that expression of uPAR and PAI-1 was still significantly elevated after 48
hours of RA treatment. Later, we observed that RA treatment induces rapid extravasation of
promyelocytic cells (see page 46). It is thus possible that the enhanced expression of uPAR and
PAI-1 is associated with these cells’ invasiveness. We have also studied the effect of RA
treatment on the release of uPAR into the culture medium and noticed that concomitant with the
increased uPAR expression in these cells, the amount of suPAR also increased significantly in
the culture medium (Fig. 6).
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    Fig. 6. suPAR in the growth medium of  promyelocytic leukemia (NB4) cells
ng/ml
0
0.25
0.50
0.75
1
0
2 3 4
Control
1
Results 45
                                                                                                                                                                 
Extravasation of blast cells and promyelocytic leukemia cells in organotypic model for
vessel wall: impact of various adhesion molecules (II)
Leukemia cells have a strong tendency to invade from the blood stream into various organs,
but the mechanisms behind leukemia cell extravasation are largely unknown. Since ICAMs are
important mediators in normal leukocyte adhesion, we chose to examine their roles in leukemia
cell invasion.
We developed a novel three-dimensional organotypic model for vessel wall, in which we
studied the extravasation of normal mononuclear cells, blast cells from acute leukemia patients,
and promyelocytic leukemia cells. This model consisted of an underlying matrix lattice, made of
collagen type I purified from rat tail tendons. On the top of the collagen gel, we seeded
endothelial cells and allowed them to form a confluent cell layer (see Fig. 7). Leukemic or
peripheral mononuclear cells were loaded in suspension on the lattice. Extravasation and
infiltration of cells was followed by light microscopy. After 1 to 2 days, lattices were cast in
paraffin blocks, and sections were cut and stained with hematoxylin and eosin (HE) to visualize
the invasion of the cells.
Rapid invasion of healthy mononuclear cells and leukemic cells: inhibitory effect of ICAM-1
antibodies on extravasation
Mononuclear cells from healthy individuals invaded through endothelial cell layers into the
underlying collagen matrix in only a few hours. Immunohistochemical staining with monocyte
and lymphocyte antibodies confirmed that monocyte-macrophages and lymphocytes were both
Endothelial cells
Collagen fibers (type I)
Mononuclear blood cells from healthy
controls or from leukemia patients
Fig. 7. Organotypic model for extravasation
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able to invade through endothelial cells. Moreover, isolated blast cells from AML and ALL
patients had the capacity to extravasate in a couple of hours, and after 24 hours, most of the blast
cells were detected in the collagen matrix under the endothelial cells (see Fig. 8).
In order to evaluate the roles of different adhesion molecules (ICAM-1, -2, -3, CD11a, and
CD18) on the extravasation process, antibodies against these adhesion molecules were added to
the mononuclear cell suspension, or endothelial cells were preincubated with them. Our results
showed that extravasation both of normal mononuclear cells and of leukemia cells could be
totally inhibited with ICAM-1 antibodies. In healthy individuals, ICAM-1 antibodies inhibited
almost 90% of the invasion (13±2% of cells invaded as compared to cells treated with control
antibody). In leukemia patients, ICAM-1 antibody prevented >80% of the extravasation of blast
cells in five of six AML patients and one of two ALL patients. Antibodies to other adhesion
molecules (CD11a, CD18, ICAM-2, and ICAM-3) had some, but not significant effects on the
extravasation.
Because earlier in vitro experiments have shown that soluble ICAM-1 can bind to its counter
receptor LFA-1, we produced and purified soluble ICAM-1 protein from transfected CHO cells
in order to interfere with integrin/ICAM-1 binding and in that manner influence extravasation of
mononuclear cells. However, at the concentrations used (10-40 µg/ml), sICAM-1 protein had no
effect on the extravasation (105±9% of cells extravasated compared to control treated cells). Yet,
when ICAM-1 antibodies were preincubated with the purified sICAM-1 protein, the antibodies
lost their ability to block the extravasation of mononuclear cells.
Fig. 8. Invasion of leukemia cells in an organotypic culture
Extravasation of acute promyelocytic leukemia cells: dramatic effect of retinoic acid
Our earlier results showed that RA treatment induced uPAR and PAI-1 expression in
promyelocytic leukemia cells, and because both of these molecules are associated with the
adhesion and migration capacity of the cells, we decided to test the invasion of promyelocytic
cells in the organotypic model, and the effect of RA on the extravasation process.
HE staining of the collagen lattice.
Leukemia cells from an AML patient
(monocytic type) were allowed to invade
for 24 hours in an organotypic culture.
Bold arrows indicate endothelial cell layer
and thin arrows invaded leukemia cells.
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First, we treated promyelocytic NB4 cells, which carry the same translocation as seen in vivo
in APL cells, for 48 hours with RA. At the same time as the differentiation was induced,
promyelocytic cells began to attach and invade through the endothelial cells. Without RA
treatment, no extravasation of cells was evident. We also obtained promyelocytic leukemia cells
ex vivo from an APL patient in relapse. Notably, these cells also invaded rapidly after RA
treatment, and no extravasation was seen without the treatment.
We then studied cell-surface expression of adhesion molecules by FACS analysis before and
after RA treatment. Only ICAM-3 was detectable on the surface of control-treated cells.
However, after 48 hours of RA treatment, ICAM-1, CD11c, and CD18 were also strongly
expressed; CD11a and ICAM-2 were not induced. Since these molecules were induced by RA
treatment, we studied on the extravasation the effect of antibodies against these adhesion
molecules. ICAM-1 antibodies were, in fact, also able to inhibit the extravasation of RA-treated
NB4 cells (13±2% of cells invaded compared to the case for cells treated with control
antibodies). Antibodies against other adhesion molecules (CD11a, CD18, ICAM-2, and ICAM-
3) showed no significant effect. Similarly, purified sICAM-1 protein alone showed no effect on
extravasation, but when it was preincubated with ICAM-1 antibodies, sICAM-1 protein inhibited
the effect of the antibodies.
Elevated levels of sICAMs in leukemia patients' plasma samples at diagnosis: divergent
effects of chemotherapy on sICAM-1 vs. sICAM-2
We also examined the presence of soluble adhesion molecules (sICAM-1 and sICAM-2) in
plasma samples of acute leukemia patients at diagnosis and their possible correlation with the
clinical characteristics of the disease. Both sICAM-1 and sICAM-2 levels were increased in
acute leukemia patients. In AML patients (n=45), sICAM-1 levels were 327±21 ng/ml and in
ALL patients (n=25), 372±54 ng/ml, compared to 148±14 ng/ml in healthy controls. Plasma
sICAM-2 levels were significantly higher in ALL patients (625±110 IU/ml) than in AML
patients (297±42 IU/ml) or healthy individuals (171±12 IU/ml). No correlation between
sICAM-1 levels and WBC or tumor-cell count appeared in ALL patients (r=-0.03 and r=-0.04),
and also in AML patients the correlations were weak (r=0.45 and r=0.40). Similarly, sICAM-2
levels in AML and ALL patients correlated only weakly with the WBC count (r=0.45 and
r=0.47, respectively). Furthermore, no correlation existed between FAB classes and sICAM
levels (Fig. 9). To study the possible association between sICAM levels and therapy response,
AML patients were divided into two groups according to their responses to chemotherapy.
Neither mean sICAM-1 nor sICAM-2 levels differed between the well-responding group
(sICAM-1 303 ng/ml, sICAM-2 155 IU/ml) and poorly-responding group (316 ng/ml and 150
IU/ml, respectively). In ALL, most of the patients achieved complete remission with one to two
cycles of chemotherapy, but their levels, however, varied considerably.
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Follow-up samples were collected at 5, 14, and 28 days after start of chemotherapy to
examine the effect of treatment on sICAM levels. Only sICAM-2 levels fell to the normal
plasma levels within 2 weeks, simultaneously with the disappearance of tumor cells from
circulation. sICAM-1 levels remained elevated during one month of chemotherapy, although at
that time-point, tumor cells were no longer  detected in the circulation.
Soluble and cellular uPAR and uPA in acute leukemia patients at diagnosis:
implications for diagnosis and prognosis (III)
The expression of uPA and uPAR and their correlation with prognosis have been examined
in a large variety of adherent tumors (Andreasen et al., 2000), but in leukemia these are less well
characterized. In addition, in recent years a soluble form of uPAR (suPAR) was discovered in
human body fluids, and preliminary studies in breast and colon cancer have suggested that
suPAR may serve as a marker for prognosis and tumor recurrence in cancer patients (Stephens
et al., 1997). We therefore characterized the levels of uPA and uPAR in the plasma and on the
cell surface of patients with acute leukemia to examine whether any correlation existed between
components of the plasminogen activation system and/or prognosis of leukemia.
A total of 110 blood samples from 80 adult patients with hematological disorders were taken
at the time of diagnosis (before any cytoreductive therapy). In addition, blood samples from 21
healthy volunteers were analyzed. Acute leukemia was diagnosed in 53 of these 80 patients: 36
patients had AML, 13 ALL, and 4 a hybrid phenotype (Table 2). The other 27 hematological
disorders included lymphoma, multiple myeloma, aplastic anemia, heavy-chain disease,
idiopathic thrombocytopenia, myelodysplastic syndrome, reactive pancytopenia, hairy-cell
leukemia, and chronic myeloid leukemia (CML).
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Fig. 9. sICAM-1 in plasma in AML patients
In plasma samples collected from
AML patients at diagnosis, sICAM-
1 levels were measured with ICAM-1
ELISA. Patients  divided into groups
according to FAB classes (M0-M5;
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EDTA plasma was collected and mononuclear cells were separated by Ficoll-Hypaque
centrifugation. Cell surface antigens for uPA and uPAR were assayed with FACS analysis.
From plasma, tPA and uPA activity and uPA and uPAR antigens were measured with ELISAs.
uPA and uPAR expressed on the blast cell surface of AML patients
In healthy controls, expression of uPA and uPAR was restricted to monocytes, and
lymphocytes lacked any detectable amounts of these on their surfaces. We found in 28 of 29
patients with AML uPAR on their leukemic cell surfaces, whereas most patients with ALL were
negative for uPAR (7/9) (see Table 2 and Fig. 10). In addition, two of three patients with a
hybrid phenotype had uPAR on the cell surface. In AML patients, uPAR was expressed in all
FAB subtypes, with the highest expression in subclasses M3, M4, and M5. The expression
pattern of uPA resembled the pattern seen with uPAR: it was expressed by myeloid blasts and
not by lymphoid blasts. However, usually a smaller percentage of cells was uPA- than uPAR-
positive.
We also studied with immunohistochemistry the uPAR expression in bone marrow biopsies
of acute leukemia patients and of healthy individuals and found that uPAR is abundantly
expressed in myeloid blasts in the bone marrow. In healthy individuals, uPAR expression was
restricted to granulocytes, monocytes, and megakaryocytes; lymphoid and erythroid precursors
stained negative for uPAR.
Fig. 10. uPA and uPAR on
leukemia cell surfaces. uPA
and uPAR characterized by
FACS analysis on the blast cell
surfaces of patients with acute
leukemias. Dark curves show
staining with uPAR and uPA
antibodies, and white curves with
control antibodies.
uPAR
AML
uPA
AML
ALL ALL
Hybrid Hybrid
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Table 2A. uPAR and uPA in plasma samples and on the blast cell surfaces of patients
with AML
Plasma Cell surface
Pt. No. FAB
type
Age WBC 109/L/
Blasts (%) of WBC
suPAR
(ng/ml)
uPA
(ng/ml)
uPA
(IU/ml)
uPAR-
positive
cells of
blast cells
(%)
uPA-
positive
cells of
blast cells
(%)
Response to
therapy/
comments
1 secondary 66 3.5 / 74 2.37 0.50 0.162 27 ND RD (2)*
2 M2 50 2.9 / 2 3.01 0.75 0.216 ND ND RD (3)
3 M3 41 108.7 / 95 2.54 0.55 0.116 82 31 CR (1)
4 M4 16 3.2 / 25 1.24 0.65 0.104 94 63 CR (1)
5 M2 47 32.0 / 67 1.63 0.42 0.079 89 31 CR (1)
6 M3 70 6.7 / 92 r 0.53 0.094 98 25 CR (1)
7 M1 71 112.1 / 95 5.75 0.95 0.115 40 6 RD (3)
8 M2 32 13.2 / 74 0.73 0.50 0.151 73 39 CR (1)
9 secondary 58 10.2 / 63 2.94 0.32 0.080 14 1 RD (1)
10 M3 72 1.1 / 0 2.39 0.41 0.113 ND ND CR (1)
11 secondary 52 3.3 / 0 1.16 0.17 0.050 ND ND     RD (2)
12 M4 72 95.4 / 72 5.83 1.06 0.147 93 63 RD (3)
13 M2 59 0.6 / 0 0.81 0.31 0.051 ND ND CR (1)
14 M5 49  21.0 / 60 2.28 0.43 0.111 97 28 CR (2)
15 M1 86 170.0 / 98 11.28 2.37 0.516 0 4 died, no therapy
16 M2 19 36.0 / 86 0.99 0.36 0.083 31 ND RD (4)
17 NC 24 19.4 / 88 1.39 0.28 0.087 90 6 CR (1)
18 M2 72 4.2 / 20 r 0.62 0.109 38 5 CR (1)
19 M4 58 2.0 / 15 1.67 0.34 0.055 ND ND CR (1)
20 secondary 67 5.4 / 5 1.39 0.11 0.062 24 17 RD (3)
21 M2 73 5.6 / 34 1.21 0.09 0.065 17 16 CR (1)
22 M2 50 9.0 / 52 1.88 0.31 0.071 97 3 CR (1)
23 M0 56 25.0 / 30 5.84 1.12 0.208 62 7 RD (4)
24 M1 75 173.0 / 100 3.67 0.89 0.173 96 63 CR (1), relapse in 5
months
25 NC 64 1.9 / 10 0.68 0.32 0.065 56 26 CR (2)
26 M4 53 86.0 / 20 5.06 0.90 0.104 32 12 RD (1)
27 M2 60 1.7 / 0 r 0.28 0.056 ND ND CR (1)
28 M2 78 16.9 / 83 r 0.44 0.065 88 79 lost to follow-up
29 M2 58 0.5 / 0 1.58 0.39 0.075 ND ND CR (1)
30 M2 72 11.7 / 72 2.74 0.34 0.065 92 7 CR (1)
31 M5 52 76.0 / 86 6.04 0.37 0.077 96 96 CR (1), BMT after the secondcycle of chemotherapy
32 M0 78 9.5 / 63 2.63 0.48 0.087 93 87 RD (1)
33 M2 72 4.8 / 32 1.70 0.33 0.053 35 6 died, no therapy
34 M5 42 22.3 / 87 0.88 0.36 0.036 71 80 CR (1)
35 M4 41 88.4 / 96 8.80 1.11 0.028 92 85 CR (1), BMT after the secondcycle of chemotherapy
36 M1 62 2.9 / 37 1.33 0.42 0.043 72 4 CR (1)
Mean AML 57 33.0 / 51 2.92 0.55 0.105 65 33
Median 59 9.9 / 62 2.08 0.42 0.082 73 25
Range 16-86 0.5-173 / 0-100 0.68-
11.28
0.09-
2.37
0.028-
0.516
0-98 1-96
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Table 2B. uPAR and uPA in plasma samples and on the blast cell surfaces of patients
with ALL and hybrid leukemia
Plasma Cell surface
Pt. No. Immuno-
phenotype
Age WBC 109/L/
Blasts (%) of WBC
suPAR
ng/ml
uPA
(ng/ml)
uPA
(IU/ml)
uPAR-
positive
cells of
blast cells
(%)
uPA-
positive
cells of
blast cells
(%)
Response to
therapy/
comments
1 cALL 33 25.2 / 83 3.49 0.75 0.172 3 3 CR (1)*
2 cALL 74 4.9 / 40 r 0.42 0.082 2 2 lost to follow-up
3 cALL 48 4.4 / 18 1.48 0.51 0.092 4 6 CR (1)
4 cALL 29 40.7 / 84 2.26 0.74 0.152 3 4 CR (1)
5 cALL 27 23.6 / 45 2.66 0.72 0.171 20 12 CR (2)
6 cALL 79 1.2 / 0 1.25 0.33 0.091 ND ND CR (1)
7 cALL 61 17.0 / 24 1.55 0.47 0.100 2 1 CR (1)
8 cALL 53 9.3 / 40 1.68 0.25 0.098 3 2 CR (1)
9 T-ALL 40 4.9 / 0 0.79 0.25 0.049 ND ND CR (1)
10 cALL 62 12.8 / 53 3.52 1.27 0.212 ND ND RD (2)
11 cALL 23 1.2 / 0 0.80 0.30 0.052 ND ND CR (2)
12 cALL 67 21.4 / 90 3.14 1.37 0.287 2 3 CR (1)
13 cALL 17 2.1/ 25 2.72 0.70 0.063 10 2 CR (2)
Mean ALL 47 13.0 / 39 2.11 0.62 0.125 5 4
Median 48 9.3 / 40 1.97 0.51 0.098 3 3
Range 17-79 1.2-40.7 /0-90 0.79
-3.52
0.25
-1.37
0.049
-0.287
2-20 1-12
1 hybrid 21 33.3 / 87 47.43 5.63 1.230 87 54 CR (2), bleeding
2 hybrid 29 127.0 / 82 1.56 1.22 0.377 31 4 RD (3), bleeding
3 hybrid 39 12.6 / 42 3.84 0.66 0.216 3 1 RD (2)
4 hybrid 47 2.8 / 0 11.79 2.00 0.287 ND ND CR (1)
Range 21-47 2.8-127-0/0-87 1.56
-47.43
0.66
-5.63
0.216
-1.230
3-87 1-54
Table 2 A, B, and C. uPA and uPAR in plasma and on cell surfaces in patients and healthy controls.
Plasma samples were tested for uPAR and uPA antigens and for uPA activity; results given as ng/ml for antigen
assays and IU/ml for activity assay. Values are means from three separate experiments. Cell-surface uPAR and
uPA were analyzed with FACS; results given as a percentage of positive blast cells. WBC, white blood cells;
*CR (1), (2), complete remission with one/two cycle(s) of chemotherapy; RD (1), (2), (3), residual disease after
one/two/three cycles of chemotherapy; ND, not defined; NC, not classifiable; r, reactive (see Materials and
Methods, page 41); cALL, common ALL; T-ALL, T-cell ALL; BMT, bone-marrow transplantation; ITP,
idiopathic thrombocytopenia; SLE, systemic lupus erythematosus; MDS, myelodysplastic syndrome; CML,
chronic myeloid leukemia.
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Table 2C. uPAR and uPA in plasma samples of patients with
other hematological disorders and controls
Plasma
Pt. No. Diagnosis Age WBC
109/L
suPAR
(ng/ml)
uPA
(ng/ml)
uPA
(IU/ml)
1 Low-grade B-cell disorder 34 64.9 1.40 ND 0.150
2 Heavy-chain disease 55 3.1 1.46 0.62 0.182
3 Aplastic anemia 33 2.0 0.70 0.37 0.116
4 CML, at diagnosis 59 90.6 4.62 1.16 0.272
5 CML, during IFN treatment 25 3.0 1.51 12.05 0.080
6 CML, during IFN treatment 38 4.0 1.83 1.74 0.168
7 Myeloma 50 2.1 1.45 0.48 0.110
8 Pancytopenia (drug-induced) 51 0.7 1.89 0.16 0.043
9 Aplastic anemia 26 1.5 0.52 0.32 0.080
10 Pancytopenia (due to SLE) 55 1.0 1.87 0.25 0.074
11 Aplastic anemia 26 1.9 0.55 0.27 0.065
12 ITP, SLE, thrombi 17 1.8 5.45 0.42 0.116
13 MDS 53 19.7 2.62 0.37 0.123
14 ITP 26 1.0 1.16 0.14 0.069
15 Cytopenia (due to infection) 22 7.7 2.81 0.60 0.110
16 MDS 33 2.3 1.03 0.28 0.079
17 Cytopenia (due to infection) 51 3.2 r 0.37 0.083
18 Hairy-cell leukemia 53 2.5 0.64 0.41 0.070
19 Monocytosis NUD 63 15.8 1.04 0.15 0.038
20 MDS 27 2.1 0.17 0.30 0.054
21 MDS (later, AML) 68 1.8 3.05 0.56 0.073
22 CML 61 60.2 2.58 0.43 0.085
23 Hairy cell leukemia 34 30.0 1.35 0.34 0.064
24 Myelofibrosis 31 9.7 1.37 0.20 0.042
25 Follicular lymphoma 57 24.9 0.84 1.22 0.057
26 Cytopenia NUD (later, ALL) 63 0.3 2.08 0.60 0.056
27 Cytopenia (drug-induced) 74 1.1 0.71 0.46 0.039
Range 17-74 0.3-
90.6
0.17-
5.45
0.14-
12.05
 0.038-
0.272
1-21 Healthy controls
Mean Control 39 1.14 0.32 0.096
Median 39 1.11 0.32 0.094
Range 24-61 0.79-
1.72
0.14-
0.60
 0.070-
0.153
Increased plasma suPAR levels in AML patients: correlation with prognosis
Patients with AML and ALL had significantly higher levels of suPAR in their plasma than
did healthy controls (2.92±0.44 ng/ml in AML, p<0.005; 2.11±0.29 ng/ml in ALL, p<0.005 vs.
1.14±0.06 ng/ml in healthy individuals). The highest plasma suPAR value, 47.4 ng/ml, was for a
patient with a hybrid phenotype. Blast cells of that patient also expressed uPAR. Values for
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suPAR showed no correlation with serum C-reactive protein levels, D-dimer values, or WBC
count.
Of 32 AML patients, 10 had high plasma suPAR levels (>2.9 ng/ml, mean level in AML
patients), 8 of these 10 patients actually failed to respond to chemotherapy or relapsed within a
short time (5 months after start of therapy) (see Fig. 11). Furthermore, in only 2 of 18 well-
responding patients was the plasma suPAR level above the mean. These two patients (31 and 35
in Table 2A) had the myelomonocytic type of AML and were treated with bone-marrow
transplantation after two cycles of chemotherapy. At that time, they had an excess of blast cells
and monocytes in their bone marrow, but these cells were regarded as reactive. In contrast, a low
level of suPAR did not predict a rapid response to chemotherapy, as after several cycles of
chemotherapy six patients had normal levels of suPAR in their plasma and residual disease in
the bone marrow.
Increased levels of uPA antigen in plasma samples of leukemia patients
In addition to plasma suPAR levels, plasma uPA levels were also significantly increased in
acute leukemia patients (0.62±0.10 ng/ml in ALL, 0.55±0.07 ng/ml in AML vs. 0.32±0.02
ng/ml in healthy individuals). Most patients with high plasma uPA levels also had high plasma
suPAR levels. uPA activity was generally quite low in plasma samples from healthy individuals
and from leukemia patients, but two patients with hybrid leukemia and one AML patient showed
markedly higher plasma uPA activity (Fig. 12). Both these hybrid leukemia patients suffered
symptomatic retinal bleeding with loss of visual field at the beginning of therapy. An AML
patient with high uPA activity died on the third day after diagnosis, and bleeding diathesis could
not be evaluated properly.
Fig. 11. Plasma suPAR in
AML patients at diagnosis.
Each patient is marked with a
triangle, and the Y-axis shows
suPAR values measured with
ELISA. RD, resistant disease; CR,
complete remission; BMT, bone
marrow transplantation. Patient
numbers are presented in Table 2A.
suPAR
15 Died
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Tumor-cell production of uPAR and uPAR fragments in acute leukemia patients
during chemotherapy (IV)
Although suPAR levels have been shown to be elevated in a variety of solid tumors, no
longitudinal studies have addressed the behavior of suPAR during chemotherapy treatment. In
addition, the source of excess suPAR in cancer patients has not been discovered. As we have
observed that in leukemia patients, and especially in AML patients, suPAR levels were elevated at
the time of diagnosis, we continued our project in acute leukemia and studied uPAR in plasma,
urine, and in tumor cells in acute leukemia patients during chemotherapy and also in healthy
individuals.
Follow-up samples (blood and urine) were collected from patients with acute leukemia
(n=35) at 5, 14, 28, and 56 days after start of chemotherapy (total samples=151). Of 35 patients,
25 had AML, 8 had ALL, and 2 were diagnosed with hybrid leukemia. Samples from 40 healthy
individuals served as controls. From the EDTA blood samples, plasma and mononuclear cells
were separated and lysates made. In addition, bone-marrow aspirates were collected from 15
patients with acute leukemia, from 6 patients with other hematological disorders, and from 5
healthy bone-marrow donors. uPAR and uPAR fragments were analyzed with ELISA and
immunoprecipitation followed by immunoblotting.
Correlations between suPAR levels and tumor-cell count in the circulation
Plasma suPAR levels were elevated in acute leukemia patients at diagnosis (2.42±0.41 ng/ml
compared to 0.82±0.04 ng/ml in healthy controls). When suPAR levels were compared to the
tumor-cell count, a significant correlation appeared (Rho=0.59, p=0.002). Especially in AML
patients, the correlation was stronger (Rho=0.69), since tumor-cell lysates of AML patients
AML     ALL    Hybrid   Control
uPA
activity
(IU/ml)
Retinal
bleeding
(patient 1)
Retinal
bleeding
(patient 2)
Died
(patient 15)
0
0.5
1.5
1.0
Fig. 12. uPA activity in
plasma samples of acute
leukemia patients at
diagnosis. Each dot marks
an individual patient, and the
y-axis shows uPA activity
values measured with ELISA.
Patient numbers are presented
in Table 2.
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contained uPAR, but ALL patients' tumor cells contained only a little or no uPAR. Furthermore,
plasma suPAR levels correlated highly with the content of uPAR in tumor cell lysates
(Rho=0.86, p=0.0004). These data strongly suggest that the excess plasma suPAR is produced
by tumor cells. To confirm that high plasma suPAR levels are not only due to the high WBC
count in acute leukemia patients, we studied chronic-phase CML patients who had extremely
high WBC counts (mean 138x109 cells/L, range 82-225x109 cells/L) and found that their
suPAR levels were still low (mean 1.07 ng/ml, range 0.65-1.49 ng/ml) with no correlation
between high WBC count and plasma suPAR level. We concluded therefore that the abundant
release of uPAR from the cell surface to the plasma is a special characteristic of malignant tumor
cells.
Rapid decrease in suPAR levels during chemotherapy
In AML patients, suPAR levels decreased to the normal plasma suPAR level within 2 weeks
of chemotherapy, at the same time as tumor cells disappeared from the circulation. That this
decrease in plasma suPAR levels correlated highly with the decrease in tumor cells in the
circulation in 2 weeks strengthens the notion that the excess plasma suPAR is derived from
tumor cells. In addition, in AML patients plasma suPAR levels at diagnosis correlated
significantly with the decrease in suPAR levels after 2 (r=0.94) and 4 weeks (r=0.95) of
treatment (Fig. 13). Patients with normal plasma suPAR levels and no tumor cells in circulation
at diagnosis showed no marked changes in suPAR levels during chemotherapy (see also Table
3).
5 10
Decrease in suPAR
level (ng/ml)
uPAR in plasma at diagnosis (ng/ml)
-2.5
0
2.5
5
7.5
10
( )
( )At 2 weeks
At 4 weeks
Fig. 13. suPAR at
diagnosis vs. decrease in
suPAR level during
chemotherapy. Plasma
suPAR levels were measured in
AML patients’ plasma samples
at diagnosis and during
chemotherapy. The graph shows
the correlation between suPAR
values at diagnosis and a
decrease in suPAR values in 2
or 4 weeks. Correlation
coefficients, analyzed by
Pearson correlation test, were
r=0.92 and r=0.95, respectively,
p<0.001.
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Urinary suPAR levels closely followed plasma suPAR levels at diagnosis and during
chemotherapy. The only exception was seen in urinary samples taken 5 days after the start of
chemotherapy. Those samples showed a peak in urinary suPAR, a type of peak not observed in
blood samples. Because the increase in urinary suPAR levels 5 days after start of chemotherapy
correlated with the decrease in tumor-cell count at the same time, the urinary suPAR peak may
be a reflection of massive tumor cell death in the body and of accumulation of suPAR in the
urine (see Table 3).
Expression patterns of uPAR fragments in leukemia patients and in healthy controls
Since proteolytic cleavage of uPAR induces a potent chemotactic response in vitro, it was of
interest to study whether these fragments exist in vivo in blood and urine samples of leukemia
patients. In leukemia cells of AML patients, both full-length receptor and a fragment
corresponding to domains D2+D3 existed. In contrast, mononuclear cells of healthy controls
contained only the full-length receptor, and cell lysates of ALL patients usually had no uPAR.
The same phenomenon was observed in peripheral blood plasma samples and in plasma samples
of bone marrow aspirates. In AML patients, fragmented uPAR was more visible in plasma
samples of bone marrow aspirates than in samples of peripheral blood. This may have been due
to the higher local concentration of tumor cells in the bone marrow. In bone marrow aspirates of
healthy controls or of patients with chronic leukemia, only full-length uPAR appeared. When we
analyzed plasma samples of bone marrow aspirates with zymography, we noticed that the
samples with higher amounts of fragmented receptor had more active uPA than did samples
containing only full-length receptor (Fig. 14).
A B C         D
uPA  tPA  __    A  _   __    B__     __    C_   _    D_
The first two lanes show lysis bands from uPA
and tPA standards; lanes A, samples from
healthy controls; B, samples from AML
patients with cleaved uPAR in bone-marrow
aspirates; C, AML patients with only full-
length receptor in the bone marrow; and lane D,
CML patient with no cleaved receptor in the
marrow.
Fig. 14. Zymogram of plasma samples from bone-marrow aspirates
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Table 3.     Summary of AML patient data
Code FAB
type
Treated
with
chemo-
therapy
Age Circ.
blast cells
at dg
(109/L)
uPAR
(ng/mg)
in cell
lysates
suPAR in plasma (ng/ml)
at day
  0     5      14    28    56
suPAR in urine (ng/mg)
at day
  0      5     14    28    56
A1 M4 Yes 65 39 1.20 10.5 7.1 1.5 1.2 † 23.1 29.6 16.3 8.1 †
A2 M2 Yes 67 14 - 1.0 1.1 0.8 0.7 0.6 2.9 4.4 1.4 2.3 2.2
A3 M2 Yes 66 61 0.45 2.6 2.3 1.2 0.9 0.8 5.4 10.7 2.6 1.6 1.7
A4 M4 Yes 36 17 0.30 3.5 3.5 4.4 3.6 1.2 9.7 10.0 16.0 9.1 4.7
A5 NC No 74 26 0.40 3.2 4.9 † - - 19.8 20.3 † - -
A6 M0 Yes 65 0 0.20 1.0 0.9 † - - 1.8 2.1 † - -
A7 M2 Yes 66 0.4 0.20 R R R R - 1.8 5.2 13.6 4.9 -
A8   NC Yes 42 5 ND 0.8 0.8 0.8 0.9 - 2.7 5.3 3.1 6.7 -
A9 M2 Yes 51 84 0.30 1.7 1.2 0.7 0.6 1.0 7.7 - 2.2 1.3 2.8
A10 M1 No 63 58 0.20 1.6 † - - - 7.6 † - - -
A11 M2 Yes 51 16 0.25 1.7 1.7 1.2 1.1 1.1 4.0 13.6 1.7 1.2 9.8
A12 M7 Yes 61 1 0.15 R R R R R 1.9 2.0 4.5 3.8 4.3
A13 M2 Yes 66 9 - 1.9 - 1.2 † - - - 18.7 † -
A14 M4 Yes 46 82 0.25 2.3 1.3 0.9 1.0 0.4 - 2.5 10.6 12.3 3.3
A15 M2 Yes 23 34 0.08 1.5 1.6 0.7 1.0 0.5 2.5 8.8 3.2 2.4 0.9
A16 M0 Yes 39 0 0.20 1.3 1.2 2.2 1.2 1.3 1.6 1.2 4.4 8.9 6.1
A17 M2 Yes 66 62 0.30 3.1 3.3 1.4 0.9 0.7 6.8 13.8 8.5 2.0 2.1
A18 M1 Yes 34 10 0.20 0.9 0.8 0.5 1.9 0.9 2.9 2.6 3.8 6.6 1.9
A19 M2 Yes 51 4 ND 0.7 0.5 0.9 0.9 0.6 2.4 1.1 1.8 1.6 1.3
A20 M2 Yes 78 118 0.35 2.4 1.4 0.8 0.6 0.8 3.2 3.5 2.3 2.0 2.3
A21 M2 Yes 71 74 0.50 4.5 2.5 1.0 1.6 † 3.3 3.1 2.0 4.1 †
A22 M4 Yes 61 49 0.90 3.9 2.1 1.3 0.7 0.5 4.4 2.7 1.6 1.8 1.8
A23 M5 Yes 68 67 1.45 7.9 3.5 1.2 † - 6.7 7.8 4.6 † -
A24 M2 Yes 53 1 0.20 0.8 0.5 0.6 1.4 - 4.2 2.5 0.9 4.4 -
A25 M2 Yes 48 3 - 0.4 0.3 0.4 0.6 - 0.5 0.6 0.8 1.7 -
Mean 56 33 0.37 2.6 1.9 1.2 1.2 0.8 4.7 6.7 4.8 3.9 3.2
uPAR levels were measured with ELISA, with their values at days 0, 5, 14, 28, and 56 after start of
chemotherapy. Urinary suPAR values were normalized with the amount of creatinine in urine samples. In
monocytic leukemias, abnormal monocytes were included in blast cell counts. ND: not detectable, NC: not
classified, R: reactive (see Methods, page 41), dg: diagnosis, circ.: circulating, †: died.
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Healthy individuals had both full-length uPAR and domains D2+D3 in their urine, but D1
was not usually observed. In contrast, AML patients with a high tumor-cell count had, at
diagnosis, large amounts of D1 in their urine. In the follow-up samples, the amount of D1
decreased, and the uPAR fragment pattern started to resemble the pattern seen in healthy
controls. In ALL patients, the fragment pattern at diagnosis and during chemotherapy did not
undergo any considerable change and was similar to that of healthy individuals. This all gave
further evidence that in AML patients, plasma and urinary suPAR are released from tumor cells.
Furthermore, because uPAR fragments were observed in vivo in patient samples, and as the
fragment pattern in leukemia differed considerably from that seen in healthy controls, it is
possible that these fragments may play a role in the pathophysiology of acute leukemia.
Release of soluble uPAR (suPAR) by endothelial cells and peripheral blood
mononuclear cells: effect of cell interactions on suPAR release (V)
Although our studies in leukemia showed that the excess plasma suPAR must be produced
by tumor cells, the cause for the low level of plasma suPAR in healthy individuals was still
unclear. Therefore, our aim was to study the cellular source of suPAR in plasma samples of
healthy individuals and factors influencing its release.
A variety of cell types in our body such as endothelial cells, fibroblasts, keratinocytes, smooth
muscle cells, and monocytes express uPAR. Because blood is in close contact with endothelial
cells and with various blood cells, we first chose to study the release of uPAR by these cells. We
cultured endothelial cells and peripheral blood mononuclear cells under physiological conditions
and measured suPAR in the growth medium, as well as uPAR in the cells with
immunoprecipitation, immunoblotting, immunofluorescence staining, and ELISA.
Production of suPAR by mononuclear blood cells and endothelial cells
We incubated citrated or heparinized blood from healthy individuals on a rotator at 4°C or at
37°C to find whether blood cells can release suPAR into the plasma. No increase in plasma
suPAR was observed in blood incubated at 4°C during 3 days of incubation. In contrast, in
blood incubated at 37°C, we observed a significant increase in plasma suPAR level after only
one day (0.71±0.12 ng/ml at the beginning vs. 1.32±0.21 ng/ml after one day at 37°C). Plasma
levels increased further and were 1.93±0.19 ng/ml after 3 days of incubation (Fig. 15).
Because these experiments showed that blood cells can release suPAR, we decided to analyze
more closely the release of suPAR by mononuclear leukocytes under in vitro conditions. When
purified blood mononuclear cells were cultured under physiological conditions without
stimulation, they secreted a small amount of suPAR into their culture media (0.13 ng/106 cells in
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24 hours); endothelial cells were able to release suPAR under culture conditions (0.48 ng/106
cells in 24 hours). In contrast, similarly cultured or PMA-stimulated thrombocytes were unable
to release any suPAR into the culture medium, nor was any suPAR found in thrombocyte
lysates.
Enhanced suPAR release by endothelial cells in co-culture with mononuclear cells or with
thrombocytes: cell-cell contact required
Because in the normal circulation, blood cells and endothelial cells are simultaneously present,
we examined the release of suPAR when these cells are cultured together. Unexpectedly, we
noticed that enhanced amounts of suPAR appeared in the culture media when either blood
mononuclear cells or thrombocytes were cultured together with endothelial cells. To study
whether cell-cell contact was required for enhanced suPAR release, we then co-cultured cells in
Transwell chambers. These experiments showed that soluble molecules in shared growth
medium were not sufficient to enhance suPAR release. In the co-culture media without cell-cell
contact, suPAR levels did not differ from the combined values of separately growing cells.
However, when cells were allowed to adhere to each other, enhanced release of suPAR appeared
again.
In thrombocyte-endothelial cell co-cultures, it was most likely that endothelial cells were
responsible for the enhanced suPAR release, because thrombocytes failed to produce any
suPAR. However, in mononuclear-endothelial cell co-cultures this was unclear, because both cell
types were able to release suPAR. We therefore studied uPAR in cell lysates and on cell
surfaces. In the endothelial cell lysates, after co-culturing the cells with mononuclear cells we
found higher amounts of uPAR than in the situation of endothelial cells cultured alone.
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Fig. 15. Production of
suPAR by blood cells.
Citrated or heparinized blood was
obtained from  healthy
individuals,  and plasma was
separated after 0 to 3 days of
incubation on a rotator at 4°C or
at 37°C. suPAR levels measured
with uPAR ELISA and the
mean±SE values are shown.
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Furthermore, with immunofluorescence staining, we observed that the intensity of uPAR
staining was markedly elevated in endothelial cells co-cultured with mononuclear cells, which
suggested that endothelial cells are responsible for enhanced suPAR release.
We next studied the presence of uPAR fragments from the culture media and cell lysates by
immunoprecipitation and immunoblotting. In the endothelial cell lysates, both full-length uPAR
and the D2D3 fragment existed, and noticeably, cells grown in co-cultures showed more
fragmented uPAR. Furthermore, in the co-culture growth media samples, we found all forms of
uPAR: full-length receptor and fragments D2D3 and D1. Fragment D1 has thus far been
detected only in the culture media of PMA-stimulated U937 cells and in the urine samples.
Although these results warrant consideration of the role of suPAR release in cell adhesion,
further studies are still needed to resolve the mechanical factors behind this phenomenon.
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DISCUSSION
Over the last 20 years acute leukemias have been classified according to the FAB
classification, which is based on morphological and cytochemical features. However, in recent
years, knowledge in cytogenetics has markedly increased, and also much more is known of its
significance for the outcome of the disease. Furthermore, other important features have been
recognized regarding the clinical behavior of the leukemia. Based on all this, a new WHO
classification of neoplastic diseases of the hematopoietic and lymphoid tissues was recently
launched (Harris et al., 1999). It tries to integrate genetic and clinical features with the
morphology, cytochemistry, and immunophenotype of the neoplastic cells, and in that manner, to
define disease entities which have clinical relevance. In the future, leukemias may be even more
strictly divided into subclasses according to the biological features of their malignant cells. This
could assist in planning individual modes of therapy for individual patients. It is therefore of
great importance to search for biological factors which influence disease progression. In this
work, we have tried to evaluate various components related to the pathophysiology, clinical
characteristics, and severity of the disease.
Impact of plasminogen activation in leukemia
Production of plasminogen activators by adherent tumor cells is closely related to the
migration and invasive properties of malignant cells. The importance of proteolysis is less clear
in hematopoietic malignancies than in solid tumors. Earlier studies have shown pronounced
differences in uPA-catalyzed plasminogen activation between leukemia cells and adherent cells
derived from tumors of non-hematopoietic origin (Stephens et al., 1988; Tapiovaara et al., 1991;
Stephens et al., 1992). PAs were highly expressed by cultured leukemia cells, and in contrast to
adherent tumor cells, leukemia cells had an enhanced capacity to activate pro-uPA, and mainly
the active form of uPA was released into the culture medium, indicating the proteolytic activity of
leukemia cells. In addition to these in vitro studies, only a few earlier studies have examined the
plasminogen activation system in ex vivo samples from leukemia patients (Wilson et al., 1983;
Tapiovaara et al., 1993; Plesner et al., 1994b). Furthermore, new components of the plasminogen
activation system, such as suPAR, have been discovered, and their presence and possible roles in
leukemia had not been analyzed. Therefore, we chose to study these aspects of the plasminogen
activation system in leukemia both in in vitro models and in ex vivo samples from leukemia
patients.
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Plasminogen activation system and hemostasis
Leukemia patients have an increased bleeding tendency. Much of this bleeding is due to the
thrombocytopenia caused by disruption of normal precursor cell differentiation in their bone
marrow. However, this bleeding tendency is not always attributable to thrombocytopenia. In
normal hemostasis, a fibrin clot is formed at the site of a tissue injury. When the clot is no
longer necessary, activation of plasminogen occurs, and plasmin starts to degrade the clot. In
hemostatic disorders, plasminogen can be unnecessarily activated, and plasmin as a wide-
spectrum protease can degrade almost any plasma protein. In addition, if the plasmin inhibitors
are not working properly, uncontrolled fibrinolysis will occur with a fatal outcome. This kind of
situation has been described in APL patients with DIC syndrome. Plasma samples of these
patients have been shown to contain reduced levels of α2-antiplasmin and PAI-1 and increased
levels of plasmin-α2-antiplasmin complexes (Sakata et al., 1991; Fukao et al., 1992; Dombret et
al., 1993; Dombret et al., 1995). Therefore, it has been suggested that the actual problem in DIC
is excessive fibrinolysis rather than excessive coagulation. In our in vitro model for acute
promyelocytic leukemia, we found that on the APL cell surface plasminogen can be activated
and plasmin can be formed. These results suggest that because plasmin has a potent protease
activity, it can interfere with the normal fibrinolytic balance and be a part of a cascade leading to
the excessive bleeding problems encountered in APL patients. Furthermore, we noticed that
plasmin formation is transiently induced by RA treatment, but that the overall effect of RA
treatment on plasmin formation is suppressive. This fits in well with the clinical observation that
in APL patients, RA treatment diminishes bleeding tendency. Our results on plasmin formation
in APL were obtained by use of the promyelocytic NB4 cell line, and we have not studied the
effect of RA on plasmin formation in APL cells ex vivo from patients. However, we have been
able to examine promyelocytic cells from some APL patients with FACS analysis, showing that
cells ex vivo from APL patients have both uPAR and uPA on the cell surface in increased
amounts. Recently, Menell et al. (1999) have also shown that the expression of annexin II, a
proposed receptor for tPA, is higher on the cell surface in APL patients than in other acute
leukemia patients and that after RA treatment, its expression decreases.
Our patient material included three patients with markedly high uPA activity in their plasma.
All these three also had high uPA antigen levels. Notably, although receiving prophylactic
platelet transfusions, during the first weeks of treatment two of these three patients with high
uPA activity exhibited symptomatic retinal bleeding with loss of visual field. The third patient
with high plasma uPA activity died on the third day after the start of therapy, and bleeding
diathesis could not be evaluated properly. Although this bleeding diathesis episode with high
plasma uPA activity may have been coincidental, it is noteworthy that in the other 53 patients no
clinical bleeding was observed, and although some of these patients had increased plasma uPA
protein levels, they still had normal uPA activity levels, indicating that their production of uPA
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was controlled by complex-formation with inhibitors. However, more patient data are needed to
clarify the real connection between bleeding diathesis and uPA activity, and the possible value of
uPA in therapeutic approaches.
Cell surface uPA and uPAR: diagnostic tools in leukemia?
Our results demonstrated that in acute leukemia patients, cell-surface uPAR expression is
restricted to blast cells expressing myeloid markers (in AML patients and patients with a hybrid
phenotype). Earlier studies examining uPAR on the leukemia cell surface have given rather
contradictory results (Plesner et al., 1994a; Jardi et al., 1996; Scherrer et al., 1999). Some
studies report that only blast cells from AML FAB groups M4 and M5 have uPAR on the cell
surface, and blast cells from more poorly differentiated subclasses (M0-M2) have no
intracellular or cell surface uPAR. In our material, which included patients from FAB classes
M0, M1, M2, M3, M4, and M5, we found that 28 of 29 AML patients had uPAR on the cell
surface. In addition, two of three patients with a hybrid phenotype and one ALL patient with
aberrant myeloid marker on the blast cell surface were uPAR-positive. The discrepancy of these
results for uPAR positivity may be due to the different antibodies and techniques used, and to
the source of the blast cells (peripheral blood vs. bone marrow). At the same time our studies
were published, Lanza et al. (1998) reported results on uPAR in acute leukemia cells, which are
in good accordance with our results. They also found that uPAR is expressed in blast cells of
M0 to M5 subclasses of AML and also in blasts of patients with biphenotypic leukemias.
Furthermore, they described a combination of different markers (uPAR positivity, abnormalities
in chromosome 11, and M5 FAB class), which predict a subset of AML characterized by a more
aggressive clinical course. The estimation of blast cell lineage is not always self-evident, and
additional phenotypic markers would be very useful. uPAR (CD87) could serve as such an
additional marker, because its expression seems to be restricted only to blast cells expressing
myeloid markers.
suPAR as a marker for prognosis in leukemia
In clinical work there are a few parameters, chromosomal abnormalities, for instance, which
can serve as prognostic markers in leukemia. However, the prediction of relapse is often
difficult, and early intervention is delayed. Therefore, we wanted to study both the cell-surface
and the plasma compartments of blood samples from patients with acute leukemia in an attempt
to discover whether components of the plasminogen activation system correlate with severity of
the disease. In our patient material, we noticed that in AML patients, high suPAR levels at
diagnosis correlated with poor response to chemotherapy and with relapse within a short time (5
months). Although these results suggest that suPAR level can be related to the aggressiveness of
the disease, it needs to be remembered that our series was quite small. In a large colon
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carcinoma series (591 patients), Stephens et al. (1999) showed an increasing risk of mortality
with increasing plasma suPAR level and suPAR level to be an independent prognostic marker. It
would therefore be of interest to study with a larger size patient population, whether suPAR level
is an independent prognostic marker, and whether it correlates with the long-term survival of
leukemia patients.
In our follow-up study, we aimed to define whether suPAR can be used as a follow-up
marker during therapy, and if it can predict relapse. This seemed promising at first, because we
found that suPAR levels correlate with the number of circulating blast cells, and because suPAR
levels decreased rapidly during treatment. Furthermore, there were patients who had only a
transient decrease in suPAR levels during treatment, whose levels increased again in relapse, or
if no remission was achieved. However, it seemed that the levels do not increase before blast
cells appear in the circulation, i.e., they fail to show the presence of blast cells in the bone
marrow. In addition, there were also patients who had a normal amount of suPAR at diagnosis.
In short, a multicenter study of suPAR in leukemia would be interesting and necessary to clarify
whether suPAR measurement can be used in the clinical setting as an additional prognostic tool
or in combination with other markers such as cytogenetical abnormalities.
Invasion of leukemia cells
In adults, hematopoiesis occurs mainly in the bone marrow. Precursor hematopoietic cells
divide and further differentiate there, and when they are well differentiated and mature enough,
they are released into the circulation. From the circulation, the fate of various blood cells is often
predestined, but sudden changes in the body and various stimuli can alter the circulation of
leukocytes. In leukemia, the normal differentiation of blood cells is disturbed, and immature
cells burst from the bone marrow into the circulation in an uncontrolled manner. Leukemic cells
also have the capability to invade various tissues outside the hematopoietic and lymphatic
system. Various cell-surface markers, including ICAMs, have been thought to play a role in the
homing of leukocytes and leukemia cells. They also facilitate the adhesion between leukocytes
and endothelial cells (Carlos and Harlan, 1994; Gahmberg, 1997; Gahmberg et al., 1997). In
addition to ICAMs, also many other molecules, including integrins and uPAR, are involved in
the tissue-invasion by normal leukocytes and adherent tumor cells (Chapman, 1997; Danø et al.,
1999; Preissner et al., 2000). In leukemia, because the invasion mechanism of blast cells and
factors influencing it have not been studied in detail, we examined leukemia cell invasion in
three-dimensional cultures mimicking the in vivo situation and evaluated factors which could
play a possible role in the disease progression.
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RA-induced invasion of promyelocytic leukemia cells
The effect of RA on APL cell extravasation is very pronounced. Without RA treatment,
neither promyelocytic NB4 cells nor cells ex vivo from an APL patient were able to traverse the
endothelial cell layer in the organotypic culture. However, when differentiation was induced by
RA, both of these cell types started to invade rapidly. Which molecules are responsible for this
invasion? Our results with FACS analysis and Northern blotting showed that RA induces the
expression of uPAR and PAI-1, both involved in vitronectin-dependent adhesion. Furthermore,
without RA treatment, promyelocytic cells had only ICAM-3 among the various ICAMs on their
cell surfaces, but RA treatment also induced expression of ICAM-1 and of the integrins CD11c
and CD18. Interestingly, earlier results have demonstrated that uPAR is associated with MAC-1
(CD11b/CD18) and also with other integrins. Therefore, the RA-induced extravasation of
promyelocytic cells can be the result of the combined effect of different types of adhesive
molecules. Our blocking experiments with antibodies to various adhesion molecules
demonstrated that ICAM-1 antibodies can inhibit the RA-induced extravasation. In addition, our
preliminary experiments with uPAR antibodies show that polyclonal antibodies against uPAR
do inhibit the extravasation, but monoclonal uPAR antibodies (R3 and R4) fail to inhibit it. It is
possible that the effect of polyclonal antibodies is nonspecific (perhaps due to sterical
hindrance), but it is also possible that the effect is specific and that the monoclonal antibodies
used are unable to block those important sites required for their association with other adhesion
molecules (e.g., with vitronectin and integrins). Although RA has a therapeutic effect on APL by
inducing cell differentiation, it may also have harmful side-effects. In the RA syndrome, patients
have fever and cell-infiltration which may, in part, be caused by the RA-induced changes in the
adhesion molecule profile on the cell surface (Frankel et al., 1992). If these symptoms are
caused by the induced expression of ICAMs or of uPAR, it would be difficult to develop agents
specific against leukemia cells, because these molecules are expressed on the surfaces of normal
leukocytes as well, and because they also have important functions in normal cell adhesion.
Extravasation of blast cells vs. normal mononuclear cells
It seems that same adhesion molecules take part in the extravasation process of normal
leukocytes and leukemia cells, because in both cases ICAM-1 antibodies were able to inhibit the
invasion of cells through endothelial cell layers. However, blast cells from different subclasses
of AML usually have different capabilities of invasion. In monocytic types of AML (M4/M5),
more often skin infiltrations of leukemia cells occur. Earlier studies have shown that ICAM-1
expression does not correlate with any specific AML subtype (Maio et al., 1990; Bruserud and
Ulvestad, 1999). Furthermore, our studies demonstrated no correlation between sICAM-1 level
in plasma and AML FAB class. In adherent tumor cells, uPAR expression has been associated
with a more invasive phenotype. Intriguingly, our results in AML showed that blast cells from
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M4/M5 subclasses have the highest amounts of uPAR on their surfaces. In addition, Scherrer et
al. (1999) have reported that at the mRNA level, uPAR expression is found only in M4/M5
subtypes. It is therefore possible that uPAR is related to M4/M5 blast cells’ invasive capacity.
The biological function of soluble ICAMs in adhesion is unclear. On the one hand, in vitro
sICAM-1 can bind LFA-1 when bound to the substratum (Rothlein et al., 1991; Hedman et al.,
1992), but on the other hand, sICAM-1 had no effect in our adhesion/extravasation experiments.
Furthermore, because we noticed no correlation between plasma sICAM-1 levels and the
invasive behavior of leukemia, it seems probable that soluble ICAMs in the circulation may have
no function in leukemia cell adhesion. However, shedding of ICAM-1 from the cell surface may
have some function in disease progression, since it has been shown that lower ICAM-1
expression on the leukemia cell surface is associated with the resistance of leukemia cells to the
lytic activity of lymphokine-activated killer (LAK) cells (Raspadori et al., 1993). This suggests
that leukemia cells may avoid being killed by the immune system by regulating their own
ICAM-1 expression. It would thus be important to study whether differences exist in the
adhesion molecule profile between leukemia cells in the bone marrow and in the peripheral
blood. It is possible that leukemia cells need several adhesion molecules when they escape from
the bone marrow into the circulation, and then later on, they regulate their adhesion molecule
profile by shedding these receptors from their cell surfaces. This may result in a situation in
which leukemia cells are no longer under the control of the normal immune system, and they are
able to divide and invade in an uncontrolled manner.
uPAR - a multifunctional protein. Biological function
in vivo in cancer patients?
In order to be able to grow and metastasize, malignant tumors need help from non-malignant
cells, e.g., from endothelial cells to form blood vessels in order to guarantee a sufficient nutrition
supply. It has been suggested that tumor cells recruit other cells to produce molecules that could
help the tumor cells invade. In adherent tumors, uPAR and other components of the PA system
are not always expressed by tumor cells, but by the surrounding stromal cells. However, in
many in vitro experiments, uPAR has been localized to the leading edge of migrating tumor
cells, suggesting that uPAR function is also important for tumor cells. In blood samples of
patients with various malignant adherent tumors (ovarian, bladder, colon, breast, lung, prostate,
and head and neck carcinomas) plasma/serum suPAR levels have been elevated (Pappot et al.,
1997; Stephens et al., 1997; Sier et al., 1998; Wahlberg et al., 1998; Miyake et al., 1999;
Schmidt and Hoppe, 1999; Sier et al., 1999; Stephens et al., 1999). It has not been known
whether these elevated levels are produced by tumor cells or by stromal cells. Our results in
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leukemia provided quite strong evidence that malignant tumor cells produce the excess plasma
and urine suPAR in leukemia patients. Furthermore, we have noticed in vitro that promyelocytic
NB4 leukemia cells can produce suPAR into their culture medium. However, the question still
remains open whether this soluble molecule has any biological function or is just a release
mechanism of cells for getting rid of extra uPAR on their surfaces.
The role of suPAR/uPAR in cell migration, adhesion, and chemotaxis
uPAR cleavage from the cell surface (either cleavage of the full-length receptor or of only the
ligand-binding domain) may function as a regulation mechanism for cells to control their
adherence to other cells or to the extracellular matrix. For example, in extravasation, cells need to
attach themselves to endothelial cells, and then after traversing the endothelial cell barrier, they
need to detach to be able to move on. Our in vitro experiments showed that endothelial cells
shed more uPAR when they grow in physical contact with leukocytes. It is possible that uPAR
shedding from cell surfaces may dissociate cells from integrins and decrease adherence, and in
that manner, promote cell movement. This phenomenon can occur very rapidly, and adherence
and detachment can follow each other in a cascade-like process. However, it is likely that many
other adhesion molecules participate in this process as well, and that they also have overlapping
roles. This may be the reason why uPAR knockouts did not show major differences in tumor
cell invasion, although marked effects were seen in inflammatory cell recruitment in the same
knockouts.
In vitro experiments have shown that the soluble urokinase receptor needs to be cleaved, i.e.,
the connecting peptide between domain 1 and 2 needs to exposed, before it is able to induce a
chemotactic effect in THP-1 and smooth-muscle cells (Resnati et al., 1996; Fazioli et al., 1997;
Degryse et al., 1999). In contrast, full-length uPAR is required for efficient vitronectin binding
(Wei et al., 1994; Høyer-Hansen et al., 1997a; Sidenius and Blasi, 2000), and furthermore, it has
been demonstrated that full-length uPAR is associated with β1-integrins, whereas the cleaved
form does not (Montuori et al., 1999). It therefore seems that the different forms of uPAR may
be required and be important for different functions. In this study, we found uPAR fragments in
tumor cells, and in plasma and urine samples of leukemia patients, whereas samples from
healthy individuals usually contained full-length uPAR. This difference is not likely to be
accidental. On the contrary, this suggests that these fragments may have some unknown
function in cancer pathophysiology. In the future, it would be of interest to isolate these
fragments from various samples from cancer patients and to analyze their amino acid sequences,
to see where the cleavage occurs in vivo, i.e., to discover whether or not it takes place at the site
of uPA cleavage. Furthermore, the isolated fragments could be tested in vitro, to see whether
they induce such processes as cytoskeletal reorganization, adherence of cells, or chemotaxis.
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Such studies would shed more light on the possible role of uPAR and uPAR fragments in the
pathophysiology of cancer in general, and on their significance in acute leukemia, as well.
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PERSPECTIVES
Because cancer cells resemble the body’s non-malignant cells in many ways, they are not
effectively rejected by the immune system. However, in addition to their normal functions,
cancer cells also possess advantages which assist them to overgrow normal cells. The ideal way
to treat the cancer would be to kill the cancer cells but not to affect normal cells. For example in
leukemia, this is very difficult to accomplish by means of conventional chemotherapy, since both
normal blood cells and leukemia cells are dividing cells. In addition, both these cell types have
similar phenotypic markers on their surfaces. Therefore, it is important to characterize the
special features of leukemia cells and to find any possible differences between them and normal
blood cells which could be useful in the design of future therapy.
During several decades, strong evidence has accumulated that in tumor invasion and
metastasis, the plasminogen activation system plays an important role. The new non-proteolytic
roles of the plasminogen activation system have reinforced interest in the plasminogen activation
field and also explained some old phenomena not understandable by the mechanisms of the
proteolytic functions of the plasminogen activation system. In this study, we have tried to
examine the role and the possible importance of the plasminogen activation system and of some
adhesion molecules in leukemia. Our results show that the components of the plasminogen
activation system are expressed in increased amounts in leukemia cells in vitro and in vivo and
that various drugs used in the treatment of leukemia regulate the expression level and the activity
of these components. Although our results also suggest that some of these components, such as
uPAR, can be used as diagnostic or prognostic markers in leukemia, still further studies are
needed to clarify their clinical impact. However, as general knowledge of the functions of uPAR
increases, and when our understanding of the biological role of soluble uPAR becomes clearer,
the results presented here may also contribute to the understanding of the pathophysiology of
leukemia and to better approaches in the treatment of leukemia patients.
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